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ABSTRACT

Compartment syndrome (CS) is a surgical emergency caused by elevated pressure
within a closed osseofascial compartment. It leads to microvascular dysfunction, limiting
oxygen and nutrient delivery, gas exchange, resulting in cellular anoxia, muscle necrosis
and cell death.
Currently, the only effective treatment is surgical fasciotomy. Recently, carbon
monoxide (CO) delivered via carbon monoxide releasing molecule-3 (CORM-3) has been
shown to improve microvascular perfusion and convey anti-inflammatory benefits in
animal models of CS.
The contribution of elevated hydrostatic pressure (EHP) to the pathophysiology of
CS was examined in an in vitro model of CS. We found that EHP led to increased
oxidative stress, apoptosis and structural changes within the human vascular endothelial
cells; application of CORM-3 diminished the magnitude of these detrimental responses.
The data suggest that CORM-3 provides beneficial effects by preventing endothelial
activation while preserving endothelial integrity, making CORM-3 an excellent potential
adjunct pharmacological therapeutic in CS.
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CHAPTER 1. INTRODUCTION AND HISTORICAL REVIEW

1.1 COMPARTMENT SYNDROME
Compartment syndrome (CS) is a true medical and surgical emergency, with
potential devastating consequences, caused by an elevated pressure within a closed
osseofascial compartment (Mubarak, Owen et al. 1978, Rorabeck and Clarke 1978,
Matsen, Winquist et al. 1980, Hartsock, O'Farrell et al. 1998). The intercompartmental
fascia is unyielding and as such, individual compartments have limited ability to expand;
this makes them vulnerable to small increases in intracompartmental pressure (ICP) or
decreases in volume.
The increase in pressure within the compartment leads to microvascular
dysfunction and compromise, thereby creating an ischemic environment within the
compartment. This then limits oxygen and nutrient delivery, as well as gas exchange,
resulting in cellular anoxia, muscle necrosis and eventual cell death (Sheridan and
Matsen 1975, Whitesides, Haney et al. 1975, Mubarak, Owen et al. 1978, Rorabeck and
Clarke 1978, Matsen, Winquist et al. 1980). Interestingly, the ischemic environment
occurs in the presence of patent vasculature. Acute CS can result in severe functional
impairment, permanent pain, disability, limb loss, and even death. CS may occur acutely,
following both high- and low-energy trauma, but can also present as a chronic
intermittent condition, such as exertional compartment syndrome, which is most
commonly seen in the athletic or military populations.
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Various types of injuries and medical conditions have been associated with the
development of acute CS such as fractures, contusions, burns, tight casts & dressings,
blast injuries, gunshot wounds, crush injuries, diabetes, bleeding disorders (Hope and
McQueen 2004), statin medications (Chautems, Irmay et al. 1997, Jose, Viswanathan et
al. 2004), various infections (Schnall, Holtom et al. 1994) and placing patients in
prolonged lithotomy positions for surgical procedures (Goldsmith and McCallum 1996,
Mathews, Perry et al. 2001). CS has been described in the arm, forearm, hand, buttock,
thigh, lower leg, foot, abdomen, thorax and even the orbit (Greene and Louis 1983,
Bonutti and Bell 1986, Brumback 1990, Kym and Worsing 1990, Frink, Hildebrand et al.
2010).

1.1.1 Brief Historical Review of CS
In 1881, the German surgeon Richard von Volkmann first described the clinical
sequelae of CS following traumatic supracondylar distal humerus fractures. He attributed
the devastating clinical outcome to the interruption of arterial blood supply but did not
specify the cause (von Volkmann 1881). This observation by von Volkmann was further
substantiated by Leser in 1884 who, by applying a tight bandage to the limbs of animals,
noted time dependent necrotic changes in the muscle, as well as venous congestion and
swelling (Leser 1884). In 1906, Hildebrand drew attention to the role of nerve
involvement in the pathophysiology of ischemic contractures after replicating the
experimental design of Leser, and coined the term ‘Volkmann’s contracture’ to refer to
the clinical sequelae following supracondylar distal humerus fractures (Hildebrand 1906).
In 1914, Murphy changed the narrative, and instead of speaking of arterial injuries and
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nerve involvement as underlying causes of ischemic contractures, he drew attention to
venous obstruction as the driving force behind CS. Although we now know that venous
obstruction is not a major underlying contributor of CS, Murphy importantly drew
attention to the idea that 1. elevated ICP was a main driving force in the pathophysiology,
that 2. arterial pulses were maintained during the process and finally that 3. by splitting
the underlying deep fascia, the “obstruction” could be relieved (Murphy 1914). Until this
point, treatments had been aimed towards the complications of CS and ischemia, such as
fibrosis and contractures (Rowlands and Lond 1905).
In 1926, through a series of elegant ischemia-reperfusion experiments using the
limbs of dogs, Jepson noted that elapsed time as well as increased pressure was a direct
causal factor in the pathogenesis of ischemic contractures. More importantly, he also
showed that by surgically decompressing the involved compartment, the function of the
limb could be restored (Jepson 1926).
The next significant contribution was likely from the work of Griffiths (1940),
and although he mistakenly argued (for the better part of two decades) that arterial spasm
was the root cause of the resulting ischemic contracture, his research contributed
significantly to our understanding and recognition of early clinical signs and symptoms of
CS, such as pain out of proportion, pain with passive extension and ‘puffiness’, which are
still widely taught to this day (Griffiths 1940).
The next main contribution to our understanding of CS came with the bombing
raids known as the London Blitz in the early 1940s. Patients with crushed extremities
would be taken to hospital, and a relatively stable clinical condition would quickly
deteriorate into systemic decompensation, multi-organ failure and eventual death. The
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condition became known as “crush syndrome” (Bywaters, Delory et al. 1941). This
highlighted the importance of ischemia-reperfusion in the pathogenesis of CS, rather than
strictly speaking of venous congestion and elevated ICP.
In 1975, Matsen delivered his unified theory of CS by combining all the relevant
data available to that point. The important aspects of his theory stated that CS was not
restricted only to the upper extremity, that elevated pressure was a critical feature of the
condition and finally that relieving the ICP via surgical fasciotomy was critical to avoid
the devastating sequelae (Sheridan and Matsen 1975). The importance of Matsen’s
contribution cannot be overstated, as he shifted the discourse from understanding the
underlying pathophysiology to better ways of diagnosing and treating acute CS.

1.1.2 Diagnosis of CS
The early identification, diagnosis and treatment of CS are critical in order to
relieve ICP, prevent ongoing tissue anoxia, necrosis and optimize patient outcome, as
well as prevent long-term disability. The diagnosis of CS is primarily a clinical one,
which, in certain circumstances may be supplemented by direct ICP measurements.
Understanding patient risk factors and the early identification of patient clinical signs and
symptoms are paramount in the diagnosis and appropriate management of CS. Risk
factors include male gender, age under 35, tibia fracture, high energy forearm fractures,
high energy long bone fracture and comminuted fractures.
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1.1.2.1 Clinical Diagnosis
There are several signs and symptoms that have traditionally been associated with
acute CS. They appear in a stepwise fashion, although the timing can vary significantly
from patient to patient and injury to injury (Myers 2000, Elliott and Johnstone 2003,
Olson and Glasgow 2005, Shadgan, Menon et al. 2008). For this reason, the importance
of serial and thorough clinical evaluations of all patients at risk of developing CS cannot
be overstated; currently, this is considered the standard of care in the management of CS.
The presence of symptoms should not only alert clinicians to the diagnosis of an acute
CS, but also, unfortunately, likely suggests an advanced stage of disease.
The first signs and symptoms associated with CS are usually pain out of
proportion to the apparent injury, and pain with passive stretch of the involved muscle
compartment (Whitesides and Heckman 1996). The sensitivity and specificity of these
clinical findings has been found to be between 13-19% and 97% respectively (Whitesides
and Heckman 1996, Ulmer 2002). Other symptoms associated with CS include tense and
painful muscle compartments, a persistent deep ache or burning pain, paresthesia or
increasing analgesia requirement, with the last of these being an especially important
finding in the pre-verbal pediatric population (Bae, Kadiyala et al. 2001).

1.1.2.2 Physical Examination
The first description of the clinical criteria for the diagnosis of CS was provided
by Griffiths in 1940. Griffiths established the original “four Ps”: pain out of proportion
and pain on passive stretch, paraesthesia, paralysis and ‘puffiness’ (Griffiths 1940).
Eventually, pallor and pulselessness were also added to the physical signs of CS (Cascio,
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Wilckens et al. 2005). Unfortunately, some of these physical exam findings, such as
paresthesia and paralysis, are considered late findings of established CS (McQueen,
Christie et al. 1996), and often signify that irreversible vascular, muscular and
neurological injury have likely already occurred (Matsen and Clawson 1975, Ulmer
2002). Although pulselessness was traditionally taught as one of the “5 Ps” in the clinical
diagnosis of CS, the absence of a pulse is no longer considered a feature of CS (Manjoo,
Sanders et al. 2010) and the presence of a pulse certainly does not rule out a diagnosis of
CS. Failing to identify CS and obtain a timely diagnosis is the greatest cause of adverse
clinical outcomes (Matsen and Clawson 1975, Rorabeck 1984, McQueen, Christie et al.
1996, Mars and Hadley 1998). In addition, missed CS is one of the most frequently
argued cases in the field of medico-legal litigation, and is associated with frequent and
significant judgements in the favour of the plaintiff (Bhattacharyya and Vrahas 2004).

1.1.2.3 Objective Compartment Pressure Monitoring
The direct measurement of ICP when attempting to diagnose CS, provided the
proper technique is used, is a valuable tool in the clinician’s armamentarium (Hargens
and Ballard 1995). Various measurement techniques have been described, such as needle
manometer, wick catheter, slit catheter and electronic transducer-tipped catheters
(Hargens and Ballard 1995). In order to capture the peak ICP value, measurements
should be taken at the level of the fracture, as well as additional sites up to 5 cm proximal
and distal to the injury (Heckman, Whitesides et al. 1994). In addition, pressures should
also be measured in the other compartments of the affected limb, to ensure that a CS is
not missed. The electronic transducer-tipped systems have been found to be the most
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accurate, as they do not rely on limb position or the height of the transducer. All direct
compartment pressure measurement devices have their own specific technical steps, are
user dependent, have their own advantages and disadvantages, and are not immune to
false negatives (Lawendy and Sanders 2010). Although some authors have argued that
all patients (especially young men) presenting with tibial diaphyseal fractures, high
energy fractures of the tibial metaphysis, soft tissue injuries or in patients with an
accompanied bleeding diathesis should undergo objective compartment pressure
monitoring (McQueen, Gaston et al. 2000), this is currently not the usual practice. There
are, however, several indications for using ICP monitors. These include unconscious
patients, pediatric patients, pre-verbal and non-verbal patients, patients with equivocal
signs and symptoms, patients with associated neurological injuries, or in a polytrauma
scenario (Whitesides, Haney et al. 1975, Gelberman, Garfin et al. 1981, Hargens,
Schmidt et al. 1981, Hargens, Akeson et al. 1989). In these cases, continuous
compartment pressure monitoring may help confirm clinical findings, decrease the delay
to fasciotomy and may, as a result, decrease the long-term complications of the disorder
(McQueen, Christie et al. 1996).

1.1.3 Consequences of Missed CS
The early identification and diagnosis of acute CS is critical to its successful
management, and will maximize the chances of a positive clinical outcome. The inability
to obtain a timely diagnosis is the most common cause of adverse clinical outcomes
(Matsen and Clawson 1975, Rorabeck 1984, McQueen, Christie et al. 1996, Mars and
Hadley 1998). A missed or late diagnosis of acute CS can lead to serious complications,
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such as muscle infarction, muscle and joint contractures, secondary joint and soft tissue
deformities, limb weakness and neurologic dysfunction (Whitesides and Heckman 1996).
Less common, but nonetheless important complications of missed CS include infection,
gram-negative sepsis, amputation and end-organ involvement (Whitesides and Heckman
1996). The end result of missed CS is often irreversible myoneural ischemia leading to
various degrees of permanent neuromuscular deficits and dysfunction.
The severity of the clinical outcome and dysfunction depends on the amount of
tissue affected, and can range from mild weakness and sensory changes to severe
ischemic contractures and limb dysfunction. When a sufficiently large amount of muscle
tissue is involved (often combined with a weakened and compromised immune system),
CS can lead to severe systemic complications such as crush syndrome, rhabdomyolysis,
renal failure (secondary to myoglobinuria) and systemic shock (Sanghavi, Aneman et al.
2006, West 2007).
A missed or late diagnosis can be the result of clinical inexperience, a lack of
suspicion, or a confusing clinical presentation (McQueen, Christie et al. 1996). These
situations can occur when patients present with altered pain perception, altered level of
consciousness, regional anesthesia, patient-controlled analgesia and nerve injury; all are
known risk factors for late diagnosis (Mubarak and Wilton 1997, Harrington, Bunola et
al. 2000).
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1.2 THERAPEUTIC APPROACHES TO CS
The therapeutic goals of treating acute CS are to minimize chronic, long lasting
injury and dysfunction of the involved limb, by accurately and efficiently diagnosing the
condition and restoring the compartments microcirculatory environment. This is done in
order to avoid the devastating consequences of myonecrosis, ischemic contracture and
limb dysfunction. Non-operative techniques and adjuncts have been studied in various
animal models and human case series with limited success. These nonoperative
treatments remain unproven, making surgical decompression through fasciotomy of all
involved compartments the only gold standard therapy for acute established CS, provided
it is carried out within 6-8 hours of CS onset (Eaton and Green 1972, Matsen, Winquist et
al. 1980, Rorabeck 1984, McQueen, Hajducka et al. 1996, Lawendy and Sanders 2010).

1.2.1 Fasciotomy
Fasciotomy, as a technique for the surgical treatment of patients with impeding
Volkmann’s contracture, was first described in 1911 by Bardenheuer (Bardenheuer 1911)
although at the time, he used the term ‘aponeurectomy’. Eventually, Murphy in 1914
suggested early surgical fasciotomy for the treatment of increased pressure within a
fascial-enclosed space due to hemorrhage and edema in order to prevent paralysis and
contractures (Murphy 1914). The concept of surgical fasciotomy, as described by
Murphy, is the mainstay for the treatment of CS today. The first detailed record of the
actual operative technique was provided by Benjamin (Benjamin 1957), describing the
surgical approach to the forearm. Fasciotomy is urgently performed to normalize
compartment pressures, in the hope of restoring normal perfusion to the affected tissues,
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halting the inflammatory process and ultimately preventing the devastating clinical
sequelae. After 6-8 hours, the risk of permanent tissue damage increases exponentially.
Once muscle and tissue necrosis has occurred, surgical fasciotomy is contraindicated as it
increases the risk of infection significantly. Adding to the complexity of this clinical
presentation, one often does not know the exact time of injury or the subsequent events
that have led to the patient’s current state, making decision making difficult. Therefore,
frequent serial clinical examinations and reassessment are extremely important.
Fasciotomy releases the involved compartment(s), allowing soft tissues to swell
and expand, thus allowing for an increased compartmental volume while decreasing the
ICP. Following decompression, surgical wounds are usually left open for 48-72 hours
prior to skin closure, which is often accompanied by split thickness skin grafting
(Lawendy and Sanders 2010).

1.2.1.1 Threshold for Decompression
Considering the significant cost of missing a CS, some authors have expanded the
indications of using ICP monitoring to include all traumas and fractures with a high risk
of CS (McQueen, Gaston et al. 2000). To complicate matters further, various ICP
thresholds have been proposed, at which fasciotomy should be performed, although there
is currently no clear consensus. Protocols have included absolute values of 30 mmHg, 40
mmHg and 45 mmHg (Mubarak, Owen et al. 1978, Matsen, Winquist et al. 1980,
Schwartz, Brumback et al. 1989) while others, rather than considering the absolute ICP of
a compartment, have used the difference between a compartment’s ICP and the patient’s
diastolic pressure (∆P), with 20 to 30 mmHg being considered an indication for
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fasciotomy (Whitesides, Haney et al. 1975). Most trauma surgeons prefer using this ∆P as
a cut-off measure to perform fasciotomy rather than using an absolute ICP threshold, as
this becomes more useful in hypotensive trauma patients leading to a lower overall
fasciotomy rate when compared to an absolute pressure threshold (Matsen, Winquist et
al. 1980, McQueen, Hajducka et al. 1996). A recent study by Whitney et al (2014) looked
at false positive rates of CS diagnosis based on one-time ICP measurements alone. When
using a ∆P threshold of 30 and 20 mmHg they reported a false positive rate of 35% and
24% respectively (Whitney, O'Toole et al. 2014).

1.2.1.2 Fasciotomy Techniques
Surgical fasciotomy techniques have been well described for the upper and lower
extremities as well as the trunk (McQueen, Gaston et al. 2000). Fasciotomies for CS of
the lower leg (80% of all cases), forearm and hand are among the most commonly
performed.

1.2.1.2.1 Fasciotomy in the Lower Leg
The lower leg is divided into 4 osseofascial compartments: anterior, lateral,
posterior superficial and posterior deep (Gray 2000) (Figure 1.1). The anterior
compartment is the most commonly affected in CS (Rorabeck and Macnab 1976). There
are two commonly described techniques for the surgical decompression of the lower leg:
the two-incision and single-incision, four-compartment fasciotomy.
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Figure 1.1.

Anatomy and compartments of the lower leg. The lower leg is
comprised of the tibia and fibula, with interconnecting fascial
planes separating the various muscles into anterior, lateral,
superficial posterior and deep posterior compartments.
Reproduced with permission from Lawendy and Sanders (2010).
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Some surgeons will routinely employ a two-incision (medial and anterolateral)
technique, while others perform a single anterolateral approach in patients with CS in
order to decompress both the anterior and lateral compartments, and then reassess the
remaining compartments with ICP monitors before releasing the posterior superficial and
posterior deep compartments (Tornetta, Puskas et al. 2016). Better visualization of tissue
planes, neurovascular structures and ability to assess the conditions of soft tissues have
been described as reasons to preferentially perform a two-incision approach (Lawendy
and Sanders 2010). However, both single-incision and two-incision approaches have been
shown to adequately decompress all 4 lower leg compartments (Neal, Henebry et al.
2016).

1.2.1.2.2 Fasciotomy in the Forearm
The forearm is made up of the volar compartment, the extensor compartment and
the mobile wad. The flexor compartment is divided into superficial, middle and deep
muscle layers. The dorsal extensor compartment contains superficial and deep layers
(Gray 2000).
A curvilinear incision is made, extending from proximal and medial aspect to the
elbow flexion crease, which then crosses the flexor surface of the elbow at an oblique
angle. This is then followed by moving lateral to the midline, allowing for an extensile
approach and the ability to release the carpal tunnel if needed. Medial and lateral flaps are
elevated; the lateral antebrachial cutaneous nerve is found and protected. The lacertus
fibrosis, the most proximal tether, is also released. The fascia overlying the superficial
volar compartment is then incised, as well as the mobile wad laterally. The interval
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between the flexor carpi ulnaris and the flexor digitorum superficialis is exploited to
reveal the deep volar compartment which can then also be released (Gray 2000).

1.2.1.2.3 Fasciotomy in the Hand
The hand is divided into ten compartments; these include the thenar, hypothenar,
adductor pollicis, four dorsal interossei and three volar interossei compartments (Gray
2000).
Two longitudinal incisions are centered over the index and ring fingers on the
dorsum of the hand. Soft tissues are bluntly dissected on either side of the metacarpals,
incising through the dorsal interossei muscle fascia. If the thenar and hypothenar
compartments need to be released, two separate incisions are made on the volar radial
aspect of the thumb and the volar ulnar aspect of the 5th digit, respectively. The carpal
tunnel can be released through a 4cm longitudinal incision, in line with the ring finger,
with the proximal extent being the flexor crease of the wrist. The transverse carpal
ligament is then released under direct visualization (Kalyani, Fisher et al. 2011).

1.2.1.3 Complications of Fasciotomy
Surgical fasciotomy, although being the gold standard treatment of CS, it is not
without its risks and complications. A high percentage of patients report postoperative
neurologic symptoms and chronic pain associated with their surgical wounds (Fitzgerald,
Gaston et al. 2000). Other complications include dry skin, pruritus, wound discolouration,
swelling, tendon tethering, hypertrophic scarring, ulceration and muscle herniation
(Johnson, Weaver et al. 1992, Heemskerk and Kitslaar 2003, Schmidt 2007). The risk of
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infection is also not insignificant, and can create potentially devastating complications;
this is directly related to the timing of the surgical intervention.
Fasciotomies which are delayed for greater than 12 hours have a 28% rate of
infection, while those performed early have an infection rate of 7.3% (Williams, Luchette
et al. 1997). In a retrospective study looking at a trauma patient population, Dover et al
(2011) found an early post-operative complication rate of 20%. Of these, 80%
experienced clinical symptoms which they rated as severe. On long-term follow-up, 70%
of patients experienced persistent symptoms, which severely limited them from either an
occupational or social point of view (Dover, Marafi et al. 2011, Dover, Memon et al.
2012).
Fitzgerald et al (2000) retrospectively assessed complications of fasciotomy in
both upper and lower extremities over an 8-year period (Fitzgerald, Gaston et al. 2000).
They found that one in every ten patients had chronic pain associated with their
fasciotomy wounds and more than 20% of patients covered their scars due to the aesthetic
appearance of the wound. They also found complications to be detrimental both socially
and occupationally, with 28% of patients changing their hobbies and 12% having to
change their occupation, secondary to the complications of their fasciotomy (Fitzgerald,
Gaston et al. 2000). Another post-operative complication of surgical fasciotomies is CS,
which has been found to occur in 3 to 20% of cases (Barr 2008), and is believed to be
caused by excessive post-operative scar tissue formation and/or inadequate release of
compartmental fascia (Schmidt 2007).
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1.2.2 Non-Surgical Interventions
Currently, non-operative treatment modalities for CS are utilized in cases where
surgical fasciotomy is contraindicated: when the affected limb is nonviable due to severe
ischemia, or missed CS (Schmidt 2007). Before 1911, non-operative treatment options
mainly consisted of limb mobilization and muscle stretching in order to prevent or treat
ischemic contractures. Today, the most common non operative treatment is the removal
of a cast or occlusive splints in a patient who presents with symptoms suggestive of CS.
In these cases, if symptoms persist, fasciotomy is indicated.
The consequences of a missed CS or of delaying fasciotomy are significant, as a
result, non-operative treatments have been limited to an adjunctive role to fasciotomy. It
would be beneficial to develop non-surgical modalities that could prolong the treatment
window between the onset of CS and the time where irreversible neurological, vascular
or muscular changes occur. Potential medical treatments have been described in both
animal models and human case series. These include mannitol (Better, Zinman et al.
1991), hyperbaric oxygen (Wattel, Mathieu et al. 1998), tissue ultrafiltration (Odland,
Schmidt et al. 2005), anti-inflammatories (Manjoo, Sanders et al. 2010) and anti-oxidants
(Kearns, Daly et al. 2004).

1.2.2.1 Mannitol
Mannitol is an osmotic diuretic, volume expander and free radical scavenger. It is
commonly used to acutely reduce intracranial pressure, prevent or treat acute kidney
failure secondary to crush injuries as well as treat raised intraorbital pressure. Crush
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injuries associated with CS can lead to rhabdomyolysis, acidosis, acute renal failure
(ARF) and even death (Bywaters, Delory et al. 1941, Better and Stein 1990).
The severity of rhabdomyolysis can be confirmed and clinically followed by
measuring serum creatine kinase (CK) levels. One of the most severe complications of
rhabdomyolysis is ARF, which has a mortality rate of 3-50% (Slater and Mullins 1998,
Malinoski, Slater et al. 2004). One of the tenets in the management of the crush syndrome
and rhabdomyolysis is aggressive fluid resuscitation, in an attempt to prevent both
systemic and renal complications (Odeh 1991, Malinoski, Slater et al. 2004).
Mannitol has been shown to decrease extracellular fluid volume by promoting
water and sodium excretion. It has been shown to reduce ICP in a canine model of CS
(Better, Zinman et al. 1991). Daniels et al. (1998) described the case of a healthy 19–
years old male presenting with heat stroke, who subsequently developed a lower leg CS,
and who was treated only with mannitol. The patient was discharged 10 days after his
admission to the hospital, with only “mild residual weakness” in the involved leg
(Daniels, Reichman et al. 1998).

1.2.2.2 Hyperbaric Oxygen Therapy
Hyperbaric oxygen therapy involves the medical use of oxygen at levels higher
than the atmospheric content of 21%. Hyperbaric oxygen therapy creates a 3-fold
increase in the oxygen diffusion into the tissues (Wattel, Mathieu et al. 1998). This
allows continued delivery of oxygen even in the presence of ischemia. Hyperbaric
oxygen has been described as either the main treatment, or as an adjunct for various
medical conditions, such as decompression sickness, arterial gas embolism, smoke
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inhalation, severe carbon monoxide (CO) poisoning, osteoradionecrosis, skin flap
healing, clostridial myonecrosis and CS (Leach, Rees et al. 1998).
With respect to CS, hyperbaric oxygen treatment is believed to exert its beneficial
effects on intracompartmental bleeding, swelling and edema by causing oxygen-induced
vasoconstriction and allowing oxygen perfusion at lower perfusion pressures (as are seen
in situations of CS) (Nylander, Nordstrom et al. 1987). As the interstitial edema is
decreased, flow through the microcirculation is restored, or at least improved. The benefit
of hyperbaric oxygen therapy has been reported in several ischemia-related clinical
scenarios including traumatic ischemic lesions, ulcerations, infections and open fractures
(Smith, Stevens et al. 1961, Hanson, Slack et al. 1966, Szekely, Szanto et al. 1973).
Published case studies have reported success in averting fasciotomy in patients presenting
with CS (Strauss, Hargens et al. 1983, Wattel, Mathieu et al. 1998, Gold, Barish et al.
2003); a recent case report by Karam et al. (2010) described the case of an NCAA
football player with acute paraspinal CS following weight-lifting: he was successfully
treated with forced diuresis and hyperbaric oxygen chamber treatment (Karam,
Amendola et al. 2010).
However, due to the lack of definitive evidence and the need for costly and
specialized equipment, hyperbaric oxygen is infrequently used and currently seen only as
an adjunct to, and not a substitute for, surgical fasciotomy.

1.2.2.3 Tissue Ultrafiltration
Tissue ultrafiltration (TUF) was first described as a method of analyzing the
contents of the interstitial space (Linhares and Kissinger 1992). TUF involves the
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insertion of small-diameter semi-permeable hollow fibers into the tissue compartment of
interest. The catheter is connected to suction, in order to filter interstitial fluid. This
enables researchers to not only decompress the tissues, but also analyze the extracted
fluid for biomarkers (Odland, Schmidt et al. 2005). The use of ultrafiltration in CS has
been shown to lower the intramuscular pressure while maintaining perfusion pressure
(Odland, Schmidt et al. 2005). In their porcine model of CS, using bovine serum
albumin-enriched saline infusion into the anterior compartment of the hind limb, Odland
et al. (2005) measured serum and filtrate creatinine kinase (CK) and lactate
dehydrogenase (LDH) levels over a 10 hour period. They found that the biomarker levels
were 80 times higher in the ultrafiltrate compared to the serum (Odland, Schmidt et al.
2005). Significantly lower pressures were recorded in experimental limbs connected to
negative pressure, coupled with a markedly lessened cellular injury. The authors
undertook a small human clinical trial, to test the safety and efficacy of ultrafiltration.
They examined ten patients with tibial fractures treated with intramedullary nailing with
and without tissue ultrafiltration, and found no difference in ICP between the two groups;
however, 2 patients in the control group developed CS, while none in the ultrafiltration
treatment group (Odland and Schmidt 2011).

1.2.2.4 Anti-Inflammatories
There is a significant body of evidence describing an increase in ICP as the
underlying cause of microcirculatory dysfunction. However, the significant impact of
inflammation and leukocyte activation in the pathophysiology of CS is increasingly being
recognized (Lawendy, Sanders et al. 2011, Lawendy, Bihari et al. 2015). Activated
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leukocytes directly impair perfusion, increase intravascular protein leakage, thus
contributing to tissue edema, as well as causing direct parenchymal injury (Kurose,
Anderson et al. 1994, Forbes, Carson et al. 1995, Forbes, Harris et al. 1996, Harris and
Skalak 1996).
Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of medication that
interfere with arachidonic acid metabolism, via inhibition of the cyclooxygenase (COX)
enzyme. Two isoforms have been identified: the constitutively expressed COX-1, and
inducible COX-2. COX-2 expression can be upregulated in response to inflammatory
stimuli and pro-inflammatory cytokines (Jan and Lowry 2009). Manjoo (2010), looked at
the effects of indomethacin, a selective COX-2 inhibitor, on capillary perfusion, cell
damage and inflammatory activation in a rat model of CS. They found that indomethacin
improved tissue perfusion and viability, decreased the number of non-perfused capillaries
and significantly lowered tissue injury, lending support to the suggestion that antiinflammatory treatments have the potential to reduce the damage in the presence of
elevated ICP (Manjoo, Sanders et al. 2010).

1.2.2.5 Anti-Oxidants
Ischemia-reperfusion is known to lead to a significant release of reactive oxygen
species (ROS) – extremely damaging free radicals, both locally within the tissue, as well
as from the release of activated neutrophils. Thus, the resulting tissue injury is not only
seen at the local level in skeletal muscle, but also in distant organ systems, such as the
lungs and kidneys (Xiao, Eppihimer et al. 1997, Kearns, Kelly et al. 1999). In a study by
Perler et al. (1990), the authors concluded that the most important component of CS
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appeared to be the free radical-mediated reperfusion injury: an increase in free radicals
(such as H2O2) causes direct injury to the endothelium. Furthermore, by interacting with
lymphocytes, ROS further stimulate a pro-inflammatory state by increasing cytokines
levels (e.g. TNF-ɑ and IL-8) (Perler, Tohmeh et al. 1990). These, in turn, lead to the
activation of neutrophils and these activated neutrophils then release ROS, which further
contributes to the endothelial injury.
Due to expanding knowledge regarding the contribution of oxidative damage in
CS and ischemia-reperfusion injury, various anti-oxidant therapies have been attempted,
to prevent both the local and systemic injuries. These include N-acetylcysteine (NAC),
taurine and vitamin C. NAC is a free radical scavenger that also restores the host cellular
anti-oxidant defenses by upregulating glutathione levels in the cell (Sjodin, Nilsson et al.
1989). The primary clinical use of NAC is in acetaminophen overdose, to reduce injury to
hepatocytes (Flanagan and Meredith 1991). It is also used for its nephroprotective effects
in patients with kidney failure prior to administering IV contrast (Tepel, van der Giet et
al. 2000), as well as to protect against oxidative injury in lung parenchyma (Bernard
1991). A study by Kearns et al. (1999) examining the effects of NAC in a rat model of
CS found that CS led to decreased muscle contractility and increased tissue
myeloperoxidase activity and treatment with NAC attenuated neutrophil activation and
preserved muscle contractility (Kearns, Kelly et al. 1999).
Taurine (2-aminoethane sulfonic acid) is a sulphur-containing amino acid, derived
from the metabolism of methionine. The major source of taurine is from a person’s diet.
Taurine has been implicated in the inhibition of lipid peroxidation, cell membrane
stabilization, osmoregulation, as well as modulation of calcium levels (Kingston, Kelly et
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al. 2004). Studies have found that exogenous administration of taurine can have
protective effects against ischemia-reperfusion tissue injury in the kidney, heart, liver and
skeletal muscle (Oz, Erbas et al. 1999, Wettstein and Haussinger 2000, Michalk,
Hoffmann et al. 2003, Wang, Li et al. 2005). Wang et al. (2005) found that the
administration of taurine reduced anterior compartment pressure, muscle edema, lactate
dehydrogenase and lipid peroxidation products in a rabbit model of CS (Wang, Li et al.
2005).
Vitamin C (ascorbate) is an antioxidant that has been shown to decrease or
prevent reperfusion injury in the lung and skeletal muscle, as well as to reduce oxidant
production in neutrophils (Herbaczynska-Cedro, Wartanowicz et al. 1994, Lehr, Frei et
al. 1995, Kearns, Kelly et al. 1999, Armour, Tyml et al. 2001, Kearns, Moneley et al.
2001). It has scavenging effects on hydrogen peroxide, which is an important component
for neutrophils recruitment and adhesion (Armour, Tyml et al. 2001). Vitamin C also
targets circulating neutrophils and lymphocytes (Levine, Daruwala et al. 1998). It is
believed to exert its beneficial effects by reducing neutrophil recruitment and activation,
as well as their extravasation into the tissues by altering the expression of adhesion
molecules (e.g. ICAM-1). Vitamin C has also shown promising results in
prophylactically treating complex regional pain syndrome (CRPS) or reflex sympathetic
dystrophy (Zollinger, Tuinebreijer et al. 1999). While CRPS and CS are distinct
pathological entities, they do share certain underlying physiological processes such as an
exaggerated inflammatory response, peripheral nervous system dysfunction and an
increase in circulating free radicals causing lipid membrane oxidation (Van der Laan
1997). A study by Kearns et al., 2004 using a rat cremasteric muscle model of CS, found
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that pre-treatment with Vitamin C reduced intercellular adhesion molecule-1 (ICAM-1)
expression and myeloperoxidase (MPO) activity as well as muscle swelling, while
preserving muscle contractile function (Kearns, Daly et al. 2004). Although there is a
concern that vitamin C may have pro-oxidant properties when administered at high doses
for a prolonged period of time (Podmore, Griffiths et al. 1998), it has been shown to have
a potent antioxidant effect without associated toxicity at doses less than 500mg per day
(Bendich and Langseth 1995).

1. 3 PATHOPHYSIOLOGY OF CS
The pathophysiology underlying the onset, progression and muscle necrosis
associated with CS is only partially understood. A bony or soft tissue insult, combined
with an inherently rigid and unyielding fascia which prevents volume expansion leads to
increased ICP, which, in turn, leads to microcirculatory dysfunction. This is followed by
the activation of an inflammatory cascade and tissue edema, eventually leading to
impaired gas exchange, restricted oxygen and nutrient delivery. The final common
pathway is cellular anoxia, cell death and myonecrosis.
In 1881, Volkmann was the first to suggest that limb paralysis secondary to CS
was due to the interruption in arterial blood supply, causing ischemia (von Volkmann
1881). He described the devastating hand deformity seen in the paediatric population
following a supracondylar fracture, complicated by CS. The deformity still bears his
name today. However, Volkmann was unable to describe the cause of the ischemia. Leser
in 1884 expanded on this principle and confirmed, through well-designed animal
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experiments, that muscle necrosis was a crucial part of the condition (Leser 1884).
Hildebrand in 1906 demonstrated that nerve involvement also occurred, in addition to
muscle necrosis (Hildebrand 1906). Over the last century, various theories have been
offered and expanded upon to explain the pathophysiological basis of CS. These have
included neurological injury (Thomas 1909), arterial injury and spasm (Griffiths 1940),
venous obstruction (Murphy 1914, Brooks 1922), increased ICP and pressure-induced
ischemia (Jepson 1926).
In 1940, while trying to expand on Volkmann’s findings, Griffiths suggested that
the paralysis and contractures seen were due to an underlying arterial injury with
reflexive spasms (Griffiths 1940). The idea of arterial injury and spasm as a cause of
ischemia and contractures was further supported by Watson-Jones in 1952 (Watson-Jones
1952). Foisie in 1942 believed that autonomic dysfunction mediated the arterial spasm.
As a result, he suggested that autonomic sympathetic blockade could treat CS and prevent
the complications (Foisie 1942). We now know that this was incorrect, on both a
pathophysiological and clinical basis.
The connection between ICP and subsequent ischemia was first made by Hughes
in 1948 (Hughes 1948) and in 1975, while considering the link between pressure,
ischemia, muscle injury and the importance of compartmental decompression through
fasciotomy, Matsen combined these relevant concepts into one unified theory of CS
(Matsen 1975). Through his description, Matsen confirmed that CS could occur in any
anatomical location, and was not a condition exclusive to the upper extremity. In
addition, he suggested that the increase in tissue intracompartmental pressure was a
critical underlying feature in the development of CS and furthermore, that surgical
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fasciotomy was the only effective treatment (Matsen 1975). Whitesides (1975) then
helped to define a methodology for directly measuring ICP (Whitesides, Haney et al.
1975). Initially, a threshold ICP was believed to exist above which irreversible changes
and injury would occur (Heckman, Whitesides et al. 1993). Subsequently, rather than an
absolute pressure threshold, others suggested that it is the difference between ICP and
diastolic blood pressure that was relevant, and should be considered in the assessment of
patients (Har-Shai, Silbermann et al. 1992, Heckman, Whitesides et al. 1994, Bernot,
Gupta et al. 1996).

1.3.1 Ischemia
1.3.1.1 Microvascular Dysfunction
Three theories have attempted to describe the microcirculatory dysfunction and
ischemia associated with increased tissue pressure seen in CS: microvascular occlusion
theory, critical closing pressure theory and arterio-venous gradient theory.
The microvascular occlusion theory states that CS results from capillary occlusion
caused by increased ICP. The theory postulates that increased ICP above capillary
pressure leads to a reduction in the patency of capillaries and thus subsequent blood flow.
This then creates an ischemic state, impairing gas exchange and nutrient delivery, leading
to cellular anoxia and cell death. However, a study by Hartsock et al (1998) found that
while compartment pressures could be experimentally raised well beyond the level to
cause complete cessation of capillary blood flow, collapse of capillary vessels was not
seen, essentially discrediting the microvascular occlusion theory (Hartsock, O'Farrell et
al. 1998).
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The critical closing pressure theory describes an absolute ICP above which
arteriole closure occurs, caused by an elevated differential between tissue pressure and
intravascular pressure (Burton and Yamada 1951). This would then lead to arteriolar
collapse and tissue ischemia. The validity of this theory however was put into question by
an experiment by Vollmar et al (1999) who assessed the response of arterioles, capillaries
and venules to pressure elevation and found no signs of arteriolar spasm or collapse
(Vollmar, Westermann et al. 1999).
Finally, the arterio-venous gradient theory states that CS is caused by increased
tissue pressure, which reduces the pressure gradient from the high pressure seen in the
arterial system to the low pressure on the venous side. As ICP rises, the gradient is
reduced and blood flow decreases, causing cellular anoxia and tissue injury (Matsen,
Winquist et al. 1980). This phenomenon also leads to pooling of venous blood, fluid
extravasation, interstitial edema and swelling and causes a further rise in ICP (Matsen
and Krugmire 1978). Although all three theories attempt to explain the link between
raised ICP and microcirculatory dysfunction, the AV gradient theory provides the closest
link, and is most easily reconciled with our current understanding of CS and
microcirculatory dysfunction vis-à-vis pressure gradient changes.

1.3.1.2 Low Flow Ischemia
We now know that, rather than being due to a state of complete occlusive vascular
ischemia and spasm, CS creates a microcirculatory “low flow” environment, occurring in
the presence of patent arterial vessels. Under normal conditions, microvascular perfusion
consists of predominantly continuously perfused capillaries (CPC). As the ICP rises,
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there occurs a shift in perfusion toward intermittently perfused capillaries (IPC), and
nonperfused capillaries (NPC) (Lawendy, Sanders et al. 2011, Lawendy, Bihari et al.
2015). Lawendy (2011) used intravital video microscopy (IVVM) to directly observe the
microvascular perfusion changes seen in early CS. After artificially raising ICP in a rat
model of CS, a decrease in the number of CPC (representing healthy perfusion) and an
increase in intermittent and non-perfused capillaries was found. These changes in
microvascular perfusion were accompanied by significant leukocyte activation, as well as
parenchymal injury (Lawendy, Sanders et al. 2011).
Despite the presence of microvascular dysfunction, some degree of perfusion
remains during CS, creating a “low flow” ischemic state, where CPCs are present in the
same capillary bed as IPC and NPC. NPCs have no ability for nutrient or gas exchange,
and represent a state of ischemia, unable to meet the metabolic demands of the tissue
(Lawendy, Sanders et al. 2011). This creates a partial ischemic state, which triggers an
early and significant inflammatory response (Gute, Ishida et al. 1998, Lum and Roebuck
2001, Schlag, Harris et al. 2001).
Heppenstall (1986) considered the ischemic process in CS in a canine model.
They found that the low flow ischemic state (specifically associated with CS) caused
tissue injury that was significantly greater than what was seen in a state of complete
ischemia. This finding was believed to be due to the intense inflammatory reaction
(Heppenstall, Scott et al. 1986). The association between partial ischemia and intense
inflammatory response has been substantiated by Conrad (2005), who compared partial
and complete ischemia in a murine model. Conrad’s results indicated that a partial
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ischemic state caused a significant early increase in pro-inflammatory mediators when
compared to complete ischemia (Conrad, Stone et al. 2005).
There are important distinctions which must be drawn between CS and complete
ischemia-reperfusion (I/R) injury: CS causes tissue injury and necrosis despite a patent
macrocirculatory system in the face of a palpable distal pulse (Seddon 1966). In addition,
the injury occurring as a result of CS is of greater magnitude compared to a complete
ischemic insult of the same duration (Heppenstall, Scott et al. 1986). While our
understanding of the pathophysiological basis underlying CS is not complete,
microcirculatory dysfunction caused by an ongoing ischemia-reperfusion type injury,
early leukocyte activation and a pro-inflammatory state appear to be the driving forces
behind the generation of CS, and its potentially devastating sequelae.

1.3.2 Reperfusion and Inflammation
The greatest paradigm shift with respect to our understanding of the
pathophysiology underlying CS came in 1941 during World War II. Researchers noted
the systemic clinical collapse which occurred in otherwise stable patients following the
revascularization of injured limbs. They noted a decrease in urine output, clinical
deterioration and multi-organ failure, followed by death in certain cases. Interestingly,
this occurred even when the injured limbs had been amputated (Bywaters and Beall 1941,
Bywaters, Delory et al. 1941). This led to the concept of ‘crush syndrome’, defining the
clinical entity associated with what we know today as ‘reperfusion injury’.
Reperfusion injury occurs when tissues are perfused after a period of ischemia.
This is accompanied by an intense inflammatory response, with both local and systemic
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effects. The return of oxygen during reperfusion causes the formation of reactive oxygen
species (ROS), which, along with activated neutrophils, cause the local and systemic
injury seen following reperfusion.
It has been well documented, in complete ischemia-reperfusion (I/R), that
increasing ischemia time leads to an increasing accumulation of activated leukocytes
(particularly neutrophils) in the post-capillary venules. Neutrophils contain intracellular
granules made up of various proteases and myeloperoxidase, which are very damaging to
cellular and extracellular targets. Upon activation, these granules are released into the
affected tissues. Thus, leukocyte activation leads to increased vascular permeability to
plasma protein leakage, tissue edema, and increased interstitial pressure. An increase in
interstitial pressure is believed to physically compress capillaries altering the arterial
venous gradient, leading to further failure of capillaries to reperfuse upon restoration of
blood flow. Correlation has been noted between the number of leukocytes in the
capillaries of post-ischemic tissue and the percentage of capillaries exhibiting no-reflow
(Engler, Dahlgren et al. 1986, Barroso-Aranda, Schmid-Schonbein et al. 1988, Gute,
Ishida et al. 1998).
The I/R process also leads to the expression of cell surface ischemic antigens; this
leads to complement activation cascade, which eventually results in the formation of the
membrane attack complex (MAC). In addition, cytokines are also released, providing
signals between the responding immunological cells, leading to adhesion, migration and
extravasation (Ley 2008).
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1.3.2.1 Reactive Oxygen Species (ROS)
ROS are small chemically reactive substances containing oxygen. These include
peroxides, superoxide and hydroxyl radical. ROS are formed as a normal byproduct of
the mitochondrial electron transport chain, peroxisomal fatty acid metabolism and
oxygen metabolism, and play an important role in cellular signalling as well as
maintenance of homeostasis (Toyokuni 1999).
During periods of ischemia, xanthine oxidase (XO) (an enzyme located in
microvascular endothelial cells of skeletal muscle) is converted from its oxidized
nicotinamide-adenone dinucleotide (NAD+)-dependent dehydrogenase (XDH) state into
XO (Korthuis, Granger et al. 1985, Korthuis, Grisham et al. 1988, Carden, Smith et al.
1990, Carden, Smith et al. 1991). Upon reperfusion (ie: the re-introduction of oxygen),
molecular oxygen now acts as the substrate which XO converts to ROS, such as
superoxide and hydroxyl radicals. The newly formed ROS will cause further tissue
damage by attacking cell membrane lipids, proteins and glycosaminoglycans.
Furthermore, the process will further stimulate the pro-inflammatory state, bringing
leukocytes to the affected tissues.
Under normal conditions, host cells are protected from the damaging effects of
ROS by endogenous anti-oxidants, such as superoxide dismutase, catalase and
glutathione peroxidase. During oxidative stress, when ROS overwhelm the anti-oxidant
defense of the host, ROS will damage cellular membranes, and as a result, severe
cellular/tissue damage ensues.
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1.3.2.2 Endothelial Activation
Under normal circumstances, resting endothelial cells do not interact with
leukocytes; on the contrary, they actually play a role in maintaining leukocyte quiescence
(Ley, Laudanna et al. 2007). Leukocyte quiescence is due, in part, to adhesion molecules
not being expressed (like E-selectin or VCAM-1), expressed at very low levels (like
ICAM-1), or sequestered internally (like P-selectin). In response to reperfusion injuries,
the activation of endothelial cells consists of three time-dependent stages: immediate
(within minutes), acute (within hours) and chronic (within days) (Ley and Reutershan
2006). The immediate activation of endothelial cells is triggered by inflammatory
chemokines, which leads to endothelial degranulation and contraction (Maier and Bulger
1996). P-selectin, which is normally stored within the cytoplasmic Weibel-Palade bodies,
is delivered to the cell surface and functions to facilitate leukocyte recruitment (Weibel
and Palade 1964), by interacting with the P-selectin glycoprotein ligand-1 (PSGL-1)
found on leukocytes.
The acute endothelial activation is triggered by the release of pro-inflammatory
cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β);
this leads to an upregulation of gene transcription and production of E-selectin, as well as
ICAM-1 (Kurose, Anderson et al. 1994, Gute, Ishida et al. 1998, Ley, Laudanna et al.
2007). The process appears to be reversible once the source of inflammation is resolved
(Ley, Laudanna et al. 2007).
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1.3.2.3 Cytokines/Chemokines
Cytokines and chemokines are a family of cell-derived secreted polypeptides that
act as communication messengers between cells (Feghali and Wright 1997). They can
communicate through autocrine, paracrine and/or endocrine mechanisms. Chemokines
are a subset of cytokines possessing chemotactic properties. These messengers are
responsible for cellular activation, communication, feedback loops and the initiation of
the systemic response to inflammation. The majority of cytokines are multifunctional
and, through their binding to cell surface receptors, can initiate a series of intracellular
signal transduction pathways (Feghali and Wright 1997).
Cytokines can alter the expression of various transcription factors and, therefore,
regulate gene transcription, further altering and modifying the production of cytokines
and cell surface receptors. Their effects are varied, and include synergistic and
antagonistic action, as well as exerting both negative and positive feedback regulatory
loops. They provide signals between leukocytes and endothelial cells eventually leading
to adhesion and transmigration of leukocytes (Gillani, Cao et al. 2012).
Acute inflammatory reactions, such as those seen in I/R injury and CS, are
mediated by a number of pro-inflammatory cytokines, most notably IL-1β, TNF-ɑ, IL-6,
IL-8, thromboxane A2; these are produced in the acute phase of inflammatory response.
Their upregulation stimulates downstream leukocyte activation and recruitment to the
involved tissues. The end result is the effects on leukocyte activation, increased reactive
oxygen species, the production and upregulation of adhesion molecules, phagocytosis and
apoptosis.
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1.3.2.3.1 TNF-a
TNA-a is a pro-inflammatory cytokine produced by macrophages following an
appropriate stimulus such as trauma, inflammation or infection (Stein and Gordon 1991).
It is one of the first cytokines released as the inflammatory process is initiated. It has
multiple functions, including being a chemoattractant for surrounding neutrophils, and is
involved in the upregulation of downstream cytokine production (Ascer, Gennaro et al.
1992). It binds to and exerts its effects through two transmembrane receptors, TNFR1
and TNFR2 (Banner, D'Arcy et al. 1993). Binding and subsequent activation leads to
altered gene transcription and protein coupling, which has been shown to initiate
programmed cell death pathways (Wallach 1997, Jiang, Wang et al. 2009). In a study by
Jiang et al. looking at hind limb ischemia in TNFR1 knockout mice, by blocking the
TNF-a/TNFR1 pathway, it was found that they could prevent the downstream actions of
TNF-a and decrease programmed cell death (Jiang, Wang et al. 2009). In a rat model of
CS, systemic levels of TNF-ɑ, along with other cytokines such as Il-1β, GRO/KC, MCP1, MIP-1a and IL-10 were found to increase in response to elevation of ICP (Donohoe
2015); however, unlike in complete I/R (characterized by TNF-ɑ spike), TNF-ɑ levels
continued to increase following fascial decompression (Lawendy, Bihari et al. 2014,
Lawendy, Bihari et al. 2016). This second rise in TNF-a levels is described by the
authors as a second hit (Lawendy, Bihari et al. 2016) and likely due to the liberation of
cellular debris, pro-inflammatory mediators and cytokines into the systemic circulation
(Lawendy, Bihari et al. 2016). The second hit and washout of debris is also significant in
that it suggests that CS, rather than being purely an I/R phenomenon is more consistent
with a pro-inflammatory state. Their research, along with previous work on the systemic
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effects of I/R, has shown that the release of TNF-a and other inflammatory cytokines in
response to a local ischemic event can cause significant systemic injury (Brock, Lawlor et
al. 1999, Lawlor, Brock et al. 1999, Lawendy, Bihari et al. 2016).

1.3.2.3.2 IL-1 β
IL-1β, like TNF-a, is a pro-inflammatory cytokine produced by activated
macrophages, and is involved in cell proliferation, differentiation and programmed cell
death (Gao, Madi et al. 2014). IL-1β has been shown to play a significant role in the I/R
literature and multiple studies have shown significant increases in IL-1β levels associated
with I/R events (Rothwell, Allan et al. 1997, Touzani, Boutin et al. 1999, Pomerantz,
Reznikov et al. 2001, Furuichi, Wada et al. 2006, Simi, Lerouet et al. 2007). Studies
utilizing IL-1β knockout mice have shown significant reduction in ischemia-induced
inflammatory responses (Furuichi, Wada et al. 2006). The same authors have further lent
credence to the idea that IL-1β mediates the injury seen in I/R injury from improvements
seen with IL-1-targeted therapy in these experimental models (Touzani, Boutin et al.
1999, Pomerantz, Reznikov et al. 2001, Furuichi, Wada et al. 2006). A study by Kalns et
al., looking at extremity CS in a pig model, in order to assess the impact of normobaric
vs. hypobaric situations in relation to CS, found that levels of IL-1β, along with TNF-a,
IL-6, FGF, IGF-1, IGF-BP4/BP5 and others were elevated in experimentally-induced CS
(Kalns, Cox et al. 2011, Kalns, Cox et al. 2011). A study by de Franciscis (2016) assessed
biomarker changes in patients with arterial occlusion and CS. All ischemic patients
experienced a significant rise in levels of IL-1, IL-6, IL-8 and TNF-a, and patients
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requiring a fasciotomy had higher levels of these pro-inflammatory mediators compared
to the patients that did not require a fasciotomy (de Franciscis, De Caridi et al. 2016).

1.3.2.4 Leukocyte Activation
The increased ICP leads to a low flow ischemic state, which is associated with
significant leukocyte activation that contributes to microcirculatory dysfunction and
leukocyte accumulation in post-capillary venules (Lawendy, Bihari et al. 2015). The
complex and regulated leukocyte activation cascade was first described in 1839 by
Rudolph Wagner (Wagner 1839). The cascade is initialized by the release of
inflammatory cytokines and chemokines, which then trigger the upregulation and
differential expression of various classes of adhesion molecules such as selectins,
integrins and Ig superfamily, on both the endothelium and leukocytes (Ley 2008).
The activation cascade is comprised of several highly regulated stages (Figure
1.2). The first step is the capture of the leukocyte by the activated endothelium. This
process is mediated by selectins, such as L-selectin on leukocytes and P-selectin and Eselectin expressed on endothelial cells. The next step is leukocyte “rolling”, whereby the
leukocyte attaches itself to the surface of the endothelium. The process then progresses to
the slow rolling stage, mediated by integrins. This is then followed by the firm adhesion
of leukocytes to the endothelium. This adhesion is further strengthened and then followed
by the clustering of integrins, which, under the appropriate stimuli, leads to leukocyte
transmigration and extravasation into the interstitium (Ley, Laudanna et al. 2007).
The process of adhesion and extravasation is mediated by members of the Ig
superfamily such as ICAM-1 and VCAM-1 on the endothelial surface, and PECAM-1 on
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neutrophils (Albelda, Muller et al. 1991, Barreiro, Yanez-Mo et al. 2002, Yang, Froio et
al. 2005). Following leukocyte extravasation into the sub-endothelial matrix and
migration towards the site of injury, a positive feedback loop is created, increasing the
permeability of the endothelium, leading to further intravascular protein extravasation.
This manifests clinically as significant interstitial edema and swelling, which in itself will
amplify the increase in ICP (Gute, Ishida et al. 1998).
Several studies have examined CS using intravital video microscopy (IVVM), a
modern technique which allows for the direct visualization of microvascular perfusion
(Manjoo, Sanders et al. 2010, Lawendy, Sanders et al. 2011, Lawendy, Bihari et al.
2014). They have demonstrated a significant increase in activated leukocytes in the postcapillary venules of skeletal muscle. Furthermore, activated leukocytes also appear to
contribute to the parenchymal injury directly, as demonstrated in neutropenic rats
(Lawendy, Bihari et al. 2015).

1.3.2.5 Complement
The complement system forms part of the innate immunity which acts as a
mediator between the innate and acquired immunity response pathways. The function of
the complement system is to clear pathogens from the host organism (Ricklin,
Hajishengallis et al. 2010). The complement cascade is made up of a series of proteins on
cell surfaces and in plasma, many of which exist as precursors, and are activated at the
site of inflammation. The complement system mediates a sequence of events that begins
with inflammatory activation and ends with pathogen opsonisation and lysis.
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Figure 1.2.

Leukocyte activation cascade. Leukocyte activation is an orderly process
comprised of leukocyte capture, rolling, adhesion and extravasation. The
individual steps are mediated by differential expression of various
adhesion molecules on both the leukocyte and the endothelium.
Adapted from Ley, Laudanna et al. 2007.
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The complement cascade is activated by IgG and IgM antibodies. There are three
known biochemical pathways that activate the complement system: the classical pathway,
the alternative pathway and the lectin pathway (Zipfel and Skerka 2009). During I/R, the
presence of ischemia antigens on cell surfaces triggers binding of circulating IgM which
subsequently leads to complement activation and formation of C3a/C3b. This is then
followed by the formation of the membrane attack complex (MAC), mediating the local
cellular injury response (Gillani, Cao et al. 2012). MAC is also involved in the
inflammatory amplification through stimulation of arachidonic acid metabolism, release
of prostaglandin E2, leukotriene B4, thromboxane B2, prostanoids, IL-1 and ROS
(Hansch, Seitz et al. 1984, Hansch, Seitz et al. 1987, Gillani, Cao et al. 2012).

Inflammatory processes such as leukocyte activation, cytokine release and the
complement cascade as well as ROS production serve a useful and protective function
including cleanup of diseased/dead cells and initiate tissue repair mechanisms.
Unfortunately, in overwhelming inflammation, as is seen in various states such as
ischemia-reperfusion injury and CS, these pathways contribute to the extensive tissue and
organ damage.

1.4 HEME METABOLISM AND OXIDATIVE STRESS
Oxygen is inherently toxic but living organisms have evolved the ability to utilize
this gas, as well as coping mechanisms to deal with oxidative stress. Most notable of
these strategies, is the presence of the heme oxygenase (HO) enzyme.
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HO degrades heme, forming equimolar amounts of biliverdin, free iron and
carbon monoxide (CO) (Ryter, Alam et al. 2006) (Figure 1.3). There are three separate
HO isoforms: the constitutively expressed HO-2 and HO-3, and the inducible HO-1
(Maines, Trakshel et al. 1986, McCoubrey, Huang et al. 1997).
The importance of CO and the HO enzyme has been shown in case reports which
detailed the death of individuals who lacked the enzyme (Yachie, Niida et al. 1999).
Several studies have demonstrated that the inhibition of HO (by pharmacological or gene
knockout means) was found to be a lethal mutation and detrimental to the host due to
heightened sensitivity to cellular stress (Poss and Tonegawa 1997, Dungey, Badhwar et
al. 2006). Conversely, the upregulation of HO (pharmacologically or through transfection
with adenovirus containing HO gene construct) has been found to be protective against
ischemia-reperfusion injury (Otterbein, Kolls et al. 1999, Otterbein, Lee et al. 1999,
McCarter, Akyea et al. 2004, McCarter, Badhwar et al. 2004) Badhwar et al. 2004).
There are case reports which have suggested that individuals with higher
expression of HO enzyme are less likely to develop diabetes, atherosclerosis, chronic
obstructive pulmonary disease and arthritis (Yamada, Yamaya et al. 2000, Brydun,
Watari et al. 2007, Wagener, Toonen et al. 2008, Song, Bergstrasser et al. 2009,
Motterlini and Otterbein 2010). As upregulation of HO is not clinically feasible, further
research has looked at the downstream byproducts of the heme degradation pathway,
particularly CO, to examine its contribution to the observed protective effects.
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Figure 1.3.

Heme degradation pathway. Heme, derived from hemoglobin, is broken
down into biliverdin by heme oxygenase (HO). Biliverdin is then
converted into bilirubin by biliverdin reductase (BVR). In this process,
carbon monoxide (CO) and free iron (Fe2+) are generated.
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1.4.1 Carbon Monoxide
Carbon monoxide (CO) is a freely diffusible gas that traverses all cell membranes.
Although considered a ubiquitous pollutant and a dangerous inhalation hazard, it is
present in every mammalian cell (Coburn 1967).

Small and regulated amounts of

intracellular CO are continuously produced: the rate of endogenous CO production is
approximately 0.42ml/hr (Coburn, Williams et al. 1967); approximately 86% of
endogenous CO production comes from the metabolism of heme, while the remaining
14% is derived from lipid oxidation, xenobiotic metabolism and other metabolic
processes (Vreman, Wong et al. 2000, Archakov, Karuzina et al. 2002). The endogenous
production of CO has been found to increase under cellular stress arising from certain
toxicological and pathological conditions (Zayasu, Sekizawa et al. 1997).
Claude Bernard, in 1857, was the first to describe the binding of CO to heme
within the hemoglobin molecule, leading to the formation of carboxyhemoglobin (COHb)
(Bernard 1857). This was then followed in 1912 by Douglas, demonstrating that the
binding of CO to heme was reversible (Douglas, Haldane et al. 1912). Importantly, the
affinity of CO for heme is approximately 240 times that of oxygen (Weaver 1999). One
molecule of hemoglobin has four oxygen binding sites. When two of the binding sites are
occupied by CO molecules (i.e. half saturation), the release of oxygen from the remaining
binding sites is inhibited, leading to a reduction in the oxygen-carrying capacity of
hemoglobin and subsequent hypoxia (Weaver 1999). By exposing the body to supraphysiologic oxygen levels, such as is seen with hyperbaric oxygen therapy, oxygen can
outcompete CO for the hemoglobin binding sites, and thus reverse the hypoxia seen with
CO poisoning (Weaver 1999, Gorman, Drewry et al. 2003).
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Under normal conditions, the majority of blood COHb comes from endogenous
production, and corresponds to blood CO levels of 0.4-1% (Vreman, Wong et al. 2000).
Symptoms of CO poisoning begin to manifest at around 20% COHb levels and include
dizziness, drowsiness, headache, vomiting and loss of motor coordination. Prolonged
exposure, and COHb levels of 50-80% will lead to respiratory difficulty, disorientation,
chest pain, loss of consciousness, coma and even death (Weaver 1999).

1.4.2 Biological Effects of Carbon Monoxide
While history has focused mostly on the negative impact of CO, namely CO
poisoning, CO plays an important and positive role in cellular communication. CO is an
important mediator of cell signalling, and appears to possess anti-ischemic, anti-oxidant,
anti-inflammatory, anti-apoptotic and vasodilatory properties (Kim, Ryter et al. 2006).

1.4.2.1 Cellular Signalling
There are currently a few known cellular mechanisms over which CO has
particular influence. The modulation of soluble guanylate cyclase (sGC) by CO and the
subsequent production of cGMP is currently the most commonly described mode of
action (Ryter and Otterbein 2004). The binding of CO to the heme domain within sGC
stimulates its activity and this leads to a significant increase in cGMP. Studies have
shown that directly subjecting vascular smooth muscle cells to CO or hypoxia (via an
increase in HO-1 and subsequently increased CO) leads to an increase in cGMP levels
(Morita, Perrella et al. 1995).
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In addition to the direct CO binding sGC signaling pathway, other indirect
pathways have been identified such as modulation of mitogen-activated protein kinases
(MAPK) and upregulation of calcium-dependent potassium channel activity (Ryter,
Otterbein et al. 2002). We do know that there is a significant interaction and cross talk
between CO and other endogenously produced gases (e.g. nitric oxide, hydrogen sulfide)
in the biologic systems (Kajimura, Fukuda et al. 2010), although the intricacies of the
underlying mechanism and signalling pathways have yet to be elucidated.

1.4.2.2 Vasodilation
Several cellular mechanisms are believed to be involved in the vasodilatory effect
of CO. CO has both “direct” (i.e. endothelial independent) effects on vascular smooth
muscles cells, as seen with the modulation of sGC and subsequent increase in cGMP, as
well as endothelial-dependent changes in the expression of vasoconstrictor factors
(Motterlini and Otterbein 2010). CO has been shown to target vascular smooth muscle
cells and is, therefore, able to have a significant vasodilatory impact, which has been
reported in the cardiac, renal, pulmonic and cerebral vasculature (Sylvester and
McGowan 1978, McFaul and McGrath 1987, Abraham and Kappas 2008). In addition to
the role played by sGC and the subsequent increase in cGMP in vasodilatory role of CO,
CO has also been shown to directly activate calcium-dependent potassium channels in the
peripheral vasculature, causing vasodilatation (Wang, Wang et al. 1997). Studies which
attempted to block the pathway using ryanodine, a known calcium channel blocker, were
able to inhibit CO-induced vasodilatation (Jaggar, Leffler et al. 2002). In addition to the
direct peripheral role of CO, there is some evidence that neural CO plays an indirect role
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in vasodilatation via signalling through the autonomic nervous system (Verma, Hirsch et
al. 1993).

1.4.2.3 Anti-Inflammatory Effects
CO has been shown to be associated with significant anti-inflammatory effects
which have been demonstrated in both in vitro and in vivo studies. For example, in an in
vitro model of sepsis, Otterbein (2000) stimulated macrophages with LPS which induced
an increase in TNF-α and other pro-inflammatory cytokines (Otterbein, Bach et al. 2000).
The exogenous administration of low-dose CO inhibited this pro-inflammatory response.
Furthermore, CO also inhibited the expression of other pro-inflammatory cytokines, such
as IL-1β and MIP-1β, while increasing the expression of IL-10, an anti-inflammatory
cytokine.
Beneficial effects of CO in relation to systemic inflammation have also been
demonstrated in in vivo experiments. When examining the impact of I/R-induced
systemic inflammatory response syndrome (SIRS), the exogenous administration of lowdose CO was able to prevent liver and small intestine microvascular dysfunction (Ott,
Scott et al. 2005, Scott, Cukiernik et al. 2009). In another study, Song et al. (2003)
performed orthotopic lung transplant in rats, which showed severe intra-alveolar
hemorrhage, a significant increase in inflammatory cellular infiltration and intravascular
coagulation. The response, however, was significantly attenuated with the exposure to
500ppm of CO; in these experiments, CO also downregulated pro-inflammatory genes
such as MIP-1α and MIF (Song, Kubo et al. 2003).
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1.4.2.4 Anti-Apoptotic Effects
To date, there have been multiple in vivo and in vitro studies demonstrating the
anti-apoptotic effects of CO. In an in vitro mouse model, TNF-α-induced apoptosis of
endothelial cells and fibroblasts was reduced following exposure to CO (Petrache,
Otterbein et al. 2000). As HO-1 protects endothelial cells (EC) from apoptosis, Brouard
(2000) were able to demonstrate that blocking the enzyme activity of HO-1 with tin
protoporphyrin (SnPPIX) leads to EC apoptosis. By exposing EC to exogenous CO, they
were able to once again prevent apoptosis in the face of HO-1 inhibition. The findings
demonstrated that the anti-apoptotic effects of HO-1 were mediated by CO and more
specifically, by the activation of the p38 MAPK pathway (Brouard, Otterbein et al.
2000).
In vivo research, examining tissue injury following I/R, found that pre-treatment
with low-dose exogenously administered CO also had anti-apoptotic effects (Ryter, Alam
et al. 2006). In a study by Abe et al. (2017), the exposure of rat kidney grafts to oxidative
stress in the presence and absence of high pressure CO found that CO significantly
improved graft function and inhibited tubular apoptosis (Abe, Yazawa et al. 2017).

1.4.3 Carbon Monoxide-Releasing Molecules (CO-RMs)
CO gas is known to be non-reactive, not expensive and easily produced. Due to
these properties, it became desirable to develop a set of compounds that could safely
carry and deliver CO to biological systems and tissues, bypassing inhalation-associated
COHb formation. Considering the known beneficial effects of HO and exogenous CO
administration, and knowing that CO binds strongly to transition metals in organic
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solvents, Motterlini et al. (2002), synthesized a novel class of transition metal carbonyls,
capable of releasing CO on demand (Motterlini, Clark et al. 2002). These carbon
monoxide-releasing molecules (CO-RMs) form carbonyl complexes, such as manganese
decarbonyl and tricarbonyl-dichloro-ruthenium dimer, which can release CO upon
activation. CO-RMs are, therefore, capable of delivering CO to the tissues in a controlled
manner, without causing a dangerous increase in COHb formation (Motterlini, Clark et
al. 2002). CO-RMs can thus be considered chemical delivery vehicles for CO.
The first CO-RM to be synthesised was CORM-1 (formula [Mn2(CO)10]). It
contains manganese at its centre, and is a rapid CO releaser (Motterlini 2007), but
requires photo-activation, thereby limiting its use to in vitro protocols. The second CORM synthesized was CORM-2 (formula [Ru(CO3Cl2)], containing a ruthenium metal
dimer at its core. CORM-2 requires organic solvent (e.g. DMSO) for CO release also
limiting its clinical use (Motterlini 2007). CORM-3 (formula [Ru(CO)3Cl(glycinate)])
was the first water-soluble ruthenium-based carbonyl that readily and rapidly releases CO
under physiological conditions (Motterlini 2007), making it an attractive compound for
clinical applications. The release of CO by CO-RMs has been validated
spectroscopically, utilising the myoglobin-binding assay (conversion of myoglobin into
carboxymyoglobin) and the biological and physiological effects of CO-RMs have been
confirmed by numerous experiments (Motterlini 2007).

1.4.4 Carbon Monoxide-Releasing Molecule-3 (CORM-3)
CORM-3 is an equimolar CO releaser under physiological conditions. CORM-3
has been shown to have beneficial vasodilatory properties in aortas (Foresti 2004),

47
positive ionotropic and anti-ischemic effect in cardiac and renal tissues (Musameh 2006;
Sandouka, 2006), and to cause mesenteric vasodilatation in cirrhotic rats (Bolognesi
2007). Furthermore, CORM-3 has been shown to have therapeutic potential in various
inflammatory conditions, such as acute liver failure induced by lipopolysaccharide (LPS)
(Yan, Yang et al. 2016), postmenopausal arthritis (Ibanez, Alcaraz et al. 2012) and also
reduced tissue injury, inflammatory response and TNF-α levels in a rat model of
hemorrhagic stroke (Yabluchanskiy, Sawle et al. 2012). The mechanism of action of
CORM-3 is unclear, but it appears to regulate the production of TNF-α, fibrinogen/fibrin,
cellular infiltration, ICAM-1 expression and the activation of transcription factors (NFκB, MAPK) (Kramkowski, Leszczynska et al. 2012). CORM-3 has also been shown to
have direct bactericidal properties against bacteria such as Pseudomonas aeruginosa
(Desmard, Davidge et al. 2009).
CO-RMs and CORM-3 have been shown to have various positive therapeutic
effects. In a rodent model of CS, the administration of CORM-3 at the time of fasciotomy
was associated with a decrease in leukocyte activation, systemic TNF-α release, and
diminished tissue injury, while improving microvascular perfusion (Lawendy et al,
2014). In a rat model of I/R injury following kidney transplantation, pre-treatment of
donor grafts with CORM-3 was shown to improve recipient survival, graft survival and
decrease serum creatinine levels compared to control (Caumartin, Stephen et al. 2011). A
study by Bihari et al., (2017), looking at I/R injury in a hind limb rat model, found that
treatment with CORM-3 improved tissue perfusion while decreasing tissue injury and
inflammatory activation (Bihari, Cepinskas et al. 2017).
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1.4.5 CORM-3 in Human CS
CORM-3 has never been tested in human patients. While the results of animal
studies employing CORM-3 as a therapeutic/interventional agent in various inflammatory
conditions look promising, CORM-3 would have to be thoroughly examined before
applying it towards human clinical pathology. The first step would be testing CORM-3 in
a relevant, reliable and reproducible in vitro model, such as that employing human
vascular endothelial cells (HUVECs).
Jaffe et al. (1973) described the process of isolating HUVECs from umbilical
cords by collagenase digestion, and used electron microscopy to demonstrate their
monolayered growth (Jaffe, Nachman et al. 1973). Since then, HUVECs have been used
extensively to study various pathological developments, such as the inflammatory
processes underlying diabetes and atherosclerosis (Onat, Brillon et al. 2011). In a study
by Caumartin et al. (2011), investigators pre-treated cultured human umbilical vein
endothelial cells with CORM-2 and found altered inflammatory state, coupled with
reduced levels of cytokines, ROS, and pro-inflammatory transcription factors (Caumartin,
Stephen et al. 2011). In addition, in an in vitro model of CS, incubating HUVECs with
serum isolated from CS patients, Bihari et al (2017) found that application of CORM-3
significantly diminished the CS-induced HUVECs monolayer breakdown, ROS
production, apoptosis, leukocyte adhesion and transmigration (Bihari, Cepinskas et al.
2017).

49
1.5 AIM OF THE THESIS
Significant gains have been made towards understanding the pathophysiology of
CS, yet much remains to be determined. Currently, surgical fascial decompression is the
only definitive treatment for CS, with current pharmacological therapies limited as
adjuncts to surgery. In order to deliver effective surgical and medical therapies, the
pathophysiological basis for the underlying condition and treatments needs to be better
understood.
The purpose of this thesis is to further expand upon the human in vitro model of
CS, developed by Bihari et al (2017), using elevation of hydrostatic pressure (EHP).
Previous experiments have demonstrated that a significant level of microvascular injury
and dysfunction develops in response to CS, as demonstrated by the loss of continuously
perfused capillaries, elevated tissue injury and a significant degree of tissue
inflammation. Unlike complete ischemia, however, CS appears to cause myonecrosis in
the face of patent vessels, implicating leukocytes as playing a primary role in both
microvascular and parenchymal injury during CS. Activated leukocytes are a major
source of inflammatory cytokines; as such, systemic neutralization of these was able to
diminish the severity of observed tissue injury, however it was unable to restore the
proper microvascular perfusion (Donohoe 2015). This would suggest that the elevated
tissue pressure itself contributes a significant amount of damage to the muscle
microcirculation (i.e. inflammation is not the only driving force behind the CS
pathophysiology), creating physical changes within the endothelial monolayer of muscle
blood vessels that lead to microvascular compromise.
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In vitro modelling of CS allows us not only to explore the underlying
pathophysiology in a mechanistic manner, but also permits interventions that are
currently not possible (or unethical) in humans. Thus, the ultimate goal of this thesis is to
further our understanding of CS pathophysiology, and to develop a safe medical adjunct
(or standalone therapy) for patients presenting with CS, avoiding (or at the least,
minimizing) the potential devastating complications of this complex condition.
This thesis is organized into four chapters. The general introduction and historical
review of CS, highlighting the advances in our understanding of diagnosis (both clinical
and through objective monitoring), therapeutic approaches and pathophysiology
(describing the microvascular dysfunction, inflammation, as well as important differences
between CS and ischemia-reperfusion injury), which have been made over the past 140
years, are summarized in Chapter 1. We introduce CO and its potential beneficial role by
underlining its biological effects, and the recent development of carbon monoxidereleasing molecules.
The response of human vascular endothelial cells (HUVECs) to elevated
hydrostatic pressure, as an in vitro model of CS, is described in Chapter 2. Outcome
measures included changes to monolayer structure, endothelial activation (measured by
assessing leukocyte adhesion to the endothelium), production of ROS and apoptosis.
The effects of CORM-3 on the magnitude of response of HUVECs to EHP are
described in Chapter 3. Relative contribution of EHP versus inflammatory mediators
(cytokines) was also assessed.
Finally, conclusions, study limitations and future directions are addressed in
Chapter 4 (General Discussion).
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CHAPTER 2. ELEVATED HYDROSTATIC PRESSURE ALTERS
ENDOTHELIAL CELLS IN AN IN VITRO MODEL OF COMPARTMENT
SYNDROME

2.1 INTRODUCTION
Compartment syndrome (CS) is a true medical and surgical emergency, with
potential devastating consequences, caused by an elevation in pressure within a closed
osseofascial compartment (Matsen, Winquist et al. 1980). The intercompartmental fascia
is unyielding (Gratz 1931) and as such, individual compartments have limited ability to
expand; this makes them vulnerable to small increases in intracompartmental pressure
(ICP) or decreases in volume. The increase in pressure within the closed compartment
leads to microvascular dysfunction and compromise, thereby creating an ischemic
environment within the compartment. This limits oxygen and nutrient delivery, as well as
gas exchange, resulting in cellular anoxia, muscle necrosis and eventual cell death
(Sheridan and Matsen 1975, Whitesides, Haney et al. 1975, Mubarak, Owen et al. 1978,
Rorabeck and Clarke 1978, Matsen 1980, Hartsock, O'Farrell et al. 1998).
The importance of various inflammatory processes is increasingly being
recognized as contributing to the pathophysiology of CS (Lawendy, Sanders et al. 2011,
Lawendy, Bihari et al. 2015). The role of activated leukocytes and the direct negative
impact they may have on capillary perfusion, including intravascular protein leakage,
leading to tissue edema and parenchymal injury is progressively being documented in the
pathophysiology of CS (Kurose, Anderson et al. 1994, Forbes, Carson et al. 1995, Forbes,
Harris et al. 1996, Harris and Skalak 1996).
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Currently, the only effective treatment for CS is surgical fasciotomy (Olson and
Glasgow 2005), with few other treatment modalities or adjuncts. Although fasciotomy is
effective, it is associated with significant (and not infrequent) complications. Some
adjunctive therapies have shown limited but promising potential in animal models
(Manjoo, Sanders et al. 2010, Lawendy, Bihari et al. 2014), but their use is hindered by
both the lack of a thorough understanding of the pathophysiological basis of CS injury,
and the lack of human models on which to develop research protocols and treatments.
The purpose of this study was to attempt to translate the recent progress which has been
made in animal studies to human subjects. To accomplish this, we developed an in vitro
model of CS using human vascular endothelial cells and elevated hydrostatic pressure.
We hypothesised that elevation of hydrostatic pressure to 30mmHg would have a
detrimental effect on the HUVECs, producing significant changes in the endothelial
monolayer, thus contributing to the breakdown of endothelial barrier. The ultimate and
hopefully eventual goal of the study is the development of a safe pharmacologic
adjunctive treatment for CS, which would reduce the morbidity and disability in patients.

2.2 MATERIALS AND METHODS
2.2.1 Reagents
Medium-199 (M199), fetal bovine serum, penicillin, streptomycin and Dulbecco’s
PBS (DPBS) (pH 7.4) were purchased from Invitrogen Canada (Life Technologies Inc.,
Burlington, ON). Dihydrorhodamine (DHR)-123 was obtained from Molecular Probes
Inc. (Eugene, OR).
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2.2.2 Cells
2.2.2.1 HUVECs
Human vascular endothelial cells (HUVECs) were isolated from human umbilical
veins by collagenase treatment, as previously described (Yoshida, Granger et al. 1992,
Cepinskas, Sandig et al. 1999, Cepinskas, Savickiene et al. 2003). Briefly, under sterile
conditions, an umbilical cord was washed with PBS; a three-way stopcock was inserted
into the umbilical vein and secured into position. Culture medium was then flushed
through the cord to remove soft tissue and blood clots, followed by an injection of
collagenase and incubation at room temperature for 30 minutes. The collected fluid and
medium was centrifuged, discarding the supernatant while resuspending the pellet in the
fresh medium.
The HUVECs were plated on parallel-flow multichannel slides (ibidi µ-Slides VI
0.4) in M199 supplemented with 10% heat-inactivated fetal bovine serum, antibiotics
(100i.u./ml penicillin, 100µg/ml streptomycin and 0.125µg/ml amphotericin B), and
incubated at 37°C in a humidified atmosphere with 5% CO2. Cell were grown to
confluence. HUVECs at passages 1-3 were used for all of the experiments.

2.2.2.2 Neutrophils
Human neutrophils, i.e. polymorphonuclear cells (PMNs), were isolated from the
venous blood of healthy adults by 1% Dextran (Sigma, Mississauga, ON) sedimentation
and gradient separation on Histopaque-1077 (Sigma, Mississauga, ON), followed by the
lysing of red blood cells with ammonium chloride solution, as previously described
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(Yoshida, Granger et al. 1992, Kuhns, Long Priel et al. 2015). Isolated leukocytes were
reconstituted in 0.1M phosphate buffered saline (PBS), pH 7.4, adjusting the buffer
volume to achieve the concentration of 1x109 leukocytes/ml. PMN viability was
confirmed by Trypan blue dye exclusion test. This procedure yielded a PMN population
that was 95–98% viable.

2.2.3 In vitro Pressure Model of CS
HUVECs were subjected to varied hydrostatic pressures (0mmHg and 30mmHg)
for 4 hours via a gravity-fed system, closed off with 3-way stopcocks. The system was
connected to a compartment pressure monitor (Synthes, Westchester, PA) to ensure
constant and uniform pressures (Figure 2.1). Both pressure groups were compared to a
control which was exposed to normal room pressure. The 0mmHg (i.e. sham group) was
included, to control for the experimental pressure set-up. All experimentation was
performed in an incubator, at 37°C. All experiments were repeated five times, on
different days, to account for any variability in ambient conditions.

2.2.4 Cellular Morphology
Morphological changes in the cell shape and integrity, as well as the integrity of
intercellular junctions were qualitatively assessed through F-actin and VE-Cadherin
immunostaining, respectively. Confluent cells were exposed to elevated hydrostatic
pressure (EHP) for 4 hours, followed by fixation in 3.7% formalin, washing three times
in 0.1M PBS, pH7.4, and solubilisation with 0.1% Triton X-100 in PBS for 15min. Cells
were then subjected to a standard immunostaining protocol for either F-actin (phalloidin
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staining) or VE-cadherin. Both Alexa Fluor 594 and Texas Red fluorochromes were
visualized with Zeiss Axiophot epifluorescence microscope using excitation/emission
wavelengths of 590/617nm, while bisbenzimide was visualized with wavelengths of
343/383nm.

2.2.4.1 F-actin Staining
Slides were incubated with 1% bovine serum albumin for 30min, followed by
6.6µM Alexa Fluor 598-labelled falloidin (F-actin stain) (Thermo Fisher Scientific,
Mississauga, ON) for 1 hour. After washing with PBS three times, slides were
coverslipped with fluorescence mounting medium (Vectashield, Vector Labs,
Mississauga, ON).

2.2.4.2 VE-cadherin Staining
Slides were incubated in 10% normal goat serum for 1 hour. After washing with
0.1M PBS, they were incubated with a polyclonal VE-cadherin antibody (Santa Cruz
Biotechnology Inc., Mississauga, ON) at 1:100 dilution for 2 hours. Slides were then
washed three times in PBS and incubated with goat-anti-mouse IgG, conjugated with
Texas Red, at 1:1000 dilution for 1 hour. Slides were then washed with PBS three times.
To visualize cell nuclei, slides were counterstained with Hoechst 33342 dye
(bisbenzimide) for 5 minutes. Following three PBS washes, cells were then coverslipped
with Vectashield and visualized by fluorescence illumination.
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Figure 2.1

The experimental setup for the elevation of hydrostatic pressure
(EHP) in the endothelial cells as an in vitro model of CS. HUVECs
were plated on multichannel slides and exposed to culture medium of
varied hydrostatic pressures via a gravity-fed system, with the system
connected to a pressure monitor.
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2.2.5 Reactive Oxygen Species (ROS) Production
The production of ROS in HUVECs was measured by intracellular oxidation of
dihydrorhodamine-123 (DHR-123), a pan-oxidant-sensitive fluorochrome, as previously
described (Mizuguchi, Stephen et al. 2009, Bihari, Cepinskas et al. 2017). DHR-123 is an
uncharged and nonfluorescent reactive oxygen species (ROS) indicator that can passively
diffuse across membranes, where it is oxidized to cationic rhodamine-123 localizing in
the mitochondria and exhibiting green fluorescence. Briefly, HUVECs (2.5x105 cells),
grown to confluence, were loaded with DHR-123 (10µM) for 45min. Following a wash
with normal M199, the cells were then subjected to elevation of hydrostatic pressure
(EHP) for 4 hours, with either 0 mmHg or 30 mmHg. Following this, the cells were
washed with PBS, lysed in 0.5% CHAPS buffer and analysed spectrofluorometrically
(FR-1501 spectrofluorometer, Shimadzu) at excitation/emission wavelengths of
495/523nm. Protein concentration in the cell lysate was assessed by DC protein assay
(BioRad, Mississauga, ON). ROS production was expressed as DHR-123 fluorescence
intensity (FI) per mg protein.

2.2.6 Quantification of Apoptosis
HUVECs were subjected to EHP of 30mmHg or 0mmHg for 4 hours, and the
level of the activation of active caspases was assessed by FAM-FLICA poly caspase
apoptosis kit (Immunochemistry Technologies, LLC), as per manufacturer’s instructions.
Briefly, cells were incubated with FAM-FLICA poly caspase reagent for one hour at
37°C, washed, detached from the slides (0.025% Trypsin in M199), plated on Lumitrac
96-well black plates Greiner Bio-One) and immediately assessed for fluorescence using
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Victor-3

plate

reader

(Perkin-Elmer),

at

excitation/emission

wavelengths

of

480nm/530nm. Levels of apoptosis were expressed as relative fluorescence units (RFU)
(i.e. fluorescence intensity/104).

2.2.7 Leukocyte (PMN) Activation – Adhesion
HUVECs grown on the parallel-flow perfusion microslides (µ-slide VI 0.4; ibidi,
Madison, WI) were subjected to EHP of 30mmHg or 0mmHg for 4 hours. Microslides
with HUVECs were then placed into an air-heated chamber (37°C) attached to an
inverted phase-contrast microscope (Diaphot 300, Nikon). Following the 10min wash
with M199 at a shear stress of 1dyn/cm2 using syringe pump (Harvard Apparatus, St.
Laurent, QC), PMNs (1x106/ml) isolated from healthy adults were added to the perfusion
medium and the perfusion was continued for 15 minutes at the same shear stress. PMNHUVECs adhesive interactions were captured in six random fields of view (10s/field)
with a digital CCD camera (Sony Corp., Japan) connected to a computer, and analyzed
offline. Adhesion was defined as PMNs that remained stationary for at least 10s. PMN
adhesion was expressed as a number of PMN/mm2.

2.2.8 Statistical Analysis
All parameters were expressed as means ± standard error of the mean (SEM), and
analyzed using one-way analysis of variance (ANOVA) (GraphPad Prism, v. 7.0, San
Diego, CA), with Bonferroni post-hoc test as needed. p<0.05 was considered statistically
significant.
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2.3 RESULTS
2.3.1 Structural Changes to Endothelium Due to EHP
Exposure of HUVECs to EHP of 30mmHg produced marked changes in F-actin
and VE-cadherin staining (Figure 2.2). Sustained EHP of 30mmHg led to prominent
stress fiber formation, as indicated by the significant increase in phalloidin labelling (a
specific marker of F-actin). Junctional VE-cadherin staining pattern was also
significantly altered, indicating gap formation within the endothelial monolayer. EHP
maintained at 0mmHg, however, did not result in any changes to F-actin or VE-cadherin
staining, both of which remained virtually identical to those seen in control cells.

2.3.2 ROS Production
Exposure of HUVECs to EHP of 30mmHg for 4 hours induced a significant
increase in the production of ROS within the endothelial cells, as shown in Figure 2.3.
DHR-123 fluorescence intensity increased from 325.0±20.1 FI/mg protein in control and
340.1±38.0 FI/mg protein in 0mmHg to 556.9±71.4 FI/mg protein in 30mmHg group
(p<0.05).

2.3.3 Apoptosis
Elevation of hydrostatic pressure to 30mmHg led to a significant increase in the
activation of caspases, as shown in Figure 2.4. The caspases activation increased from
1.7±0.5 RFI in control and 1.6±0.4 RFI in the 0mmHg groups to 4.0±0.7 RFI in 30mmHg
group (p<0.05).
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0mmHg

30mmHg

F-actin

VE-cadherin

Figure 2.2

The effect of EHP on the expression of F-actin and VE-cadherin in an
in vitro model of CS. CS stimulus, in the form of a sustained EHP at
30mmHg, led to an increase in stress fiber formation and changes to
junctional staining pattern of HUVECs.
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Figure 2.3

The effect of EHP on the level of oxidative stress within the
endothelial cells in an in vitro model of CS. CS stimulus, in the form of
sustained EHP at 30mmHg for 4 hours, led to a significant increase in
reactive oxygen species formation within HUVECs. (One-way ANOVA,
*p<0.05; N=5 per group).

Active Caspases
(Relative Fluorescence Change)
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Figure 2.4
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The effect of EHP on level of apoptosis within the endothelial cells in
an in vitro model of CS. CS stimulus, in the form of sustained EHP at
30mmHg for 4 hours, led to a significant increase in the activity of
caspases within HUVECs. (One-way ANOVA, *p<0.05; N=5 per group).
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2.3.4 PMN Adhesion
Elevation of hydrostatic pressure to 30mmHg resulted in a marked increase in
PMN activation, as demonstrated by an increase in PMN adhesion to HUVECs
monolayer under the conditions of flow. Adhesion increased from 4.0±1.5 PMNs/0.1mm2
in the control and 3.8±1.2 PMNs/0.1mm2 in the 0mmHg groups to 12.2±1.7
PMNs//0.1mm2 in the EHP of 30mmHg group (p<0.05) (Figure 2.5).

2.4 DISCUSSION
CS is associated with a complex and often times confusing diagnostic picture,
limited therapeutic options, significant complications and, unfortunately, significant
patient disability (Giannoudis, Nicolopoulos et al. 2002). While certain non-operative
adjuncts such as NSAIDs, tissue ultrafiltration and hyperbaric oxygen therapy have
shown therapeutic potential in certain animal models and small human case series
(Manjoo, Sanders et al. 2010, Lawendy, Bihari et al. 2014), their clinical use has been
limited by a lack of understanding of the pathophysiology underlying both CS and the
individual therapies as well as the lack of an effective human model on which to test
therapeutic treatments.
In the present study, we attempted to mimic the CS conditions in vitro by
subjecting human vascular endothelial cells to elevated hydrostatic pressure (the CSrelevant stimulus), directly assessing cellular response, while attempting to clarify the
role in which EHP contributes to the endothelial activation and pro-inflammatory
potential of CS. To our knowledge, this is the first study to model CS in cell culture using

PMN Adhesion
(# of leukocytes/0.1mm2)
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Figure 2.5.
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The effect of EHP on the endothelial cell activation in an in vitro
model of CS. CS stimulus, in the form of sustained EHP at 30mmHg for 4
hours, led to a significant endothelial activation, as measured by an
increase in PMN leukocyte adhesion to HUVECs. (One-way ANOVA,
*p<0.05; N=5 per group).

83
EHP as a CS-relevant stimulus. The primary goal of these studies is to further our
understanding of the pathophysiology leading to CS, as well as to allow for the
development and testing of potential interventions currently not possible (or even
unethical) in human subjects.
CS is comprised of a complex cascade of intracellular and extracellular events,
eventually creating a pro-inflammatory milieu, with the subsequent activation of vascular
endothelial cells and leukocytes. This leads to impaired cell-to-cell integrity, increased
vascular permeability, leukocyte extravasation and the formation of interstitial edema
(Sabido, Milazzo et al. 1994). The cellular and molecular basis underlying the
parenchymal injury/organ dysfunction associated with CS are also poorly understood. In
addition, there are no studies using human material to assess the health of vascular
endothelial cells in response to stimulation with a CS-like stimulus.
In the current study, exposure of HUVECs to EHP led to a rearrangement of
stress fibers and a breakdown of endothelial barrier, as evidenced by changes in F-actin
and VE-cadherin expression (Figure 2.2). This is in keeping with previous research
which found that EHP led to changes in endothelial cell morphology (Acevedo, Bowser
et al. 1993). Furthermore, alterations in cellular structure in response to EHP are not seen
to occur only in endothelial cells. In chondrocytes, EHP leads to F-actin thinning and
disorganization, as well as a decrease in cell stiffness (Cao, Xia et al. 2015). Furthermore,
Tokuda (2009) were able to show that the exposure of epithelial cells to EHP induced
dynamic changes in cell height, actin structure and intercellular junctions (Tokuda,
Miyazaki et al. 2009). Finally, Ohashi et al. (2007) found lower levels of VE-cadherin
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and changes to cell structure, as well as loss of contact inhibition in bovine aortic
endothelial cells exposed to EHP (Ohashi, Sugaya et al. 2007).
Under normal circumstances, the intact endothelium provides a semi-selective
barrier between the vessel lumen and the interstitial tissue, controlling the passage of
fluid, proteins, leukocytes and other material between the blood and the interstitium.
When the endothelium is subjected to cellular stress and inflammation, it experiences an
increase in permeability, eventually leading to tissue edema. This also creates nonperfused segments within the capillary system, further contributing to ischemia and
microvascular dysfunction (Sabido, Milazzo et al. 1994). A study by Kataoka et al.
(1998) found that subconfluent bovine aortic endothelial cells responded differently to
shear stress than confluent cells, suggesting that cell shape change is dependent on cell to
cell contact with neighbouring cells (Kataoka, Ujita et al. 1998). It has been postulated
that changes in hydrostatic pressure may enhance the synthesis of VEGF by the
endothelial cells, leading to dephosphorylation of catenins and a decrease in the
formation of adherens junctions dependent on VE-cadherin (Ohashi, Sugaya et al. 2007).
A study by Martin (2005) in renal cell lines subjected to pathological hydrostatic
pressures found that EHP leads to shortening of actin fiber length (Martin, Brown et al.
2005). Previously, Ingber proposed the “tensegrity” model, which stipulates that different
mechanical forces applied to a cell will be transmitted by actin filaments to proteins, like
integrins, which anchor the cell to the extracellular matrix; these forces can cause
reorganization of integrins into a different pattern, in order to resist those forces (Ingber
1993). In the context of CS, it is plausible to assume that the elevation of
intracompartmental pressure results in EHP, directly producing changes in the endothelial
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cell cytoskeleton (e.g. F-actin assembly) and associated adherens junction protein
function (e.g. VE-cadherin, β-catenin) (Corada, Liao et al. 2001, Giannotta, Trani et al.
2013), thus further contributing to the breakdown of endothelial barrier.
When endothelial cells were subjected to sustained EHP, a significant increase in
intracellular production of ROS was observed (Figure 2.3). Increased ROS production is
most likely due, at least in part, to changes in the mitochondrial respiratory chain. This is
in agreement with previous research in deep dive physiology, suggesting that elevated
hydrostatic pressure has direct impact on the mitochondrial respiratory chain or the inner
mitochondrial membrane (Wang, Guerrero et al. 2015). Furthermore, it can also be
surmised that an increase in ROS, as a result of EHP, will trigger downstream signalling,
stimulating inflammation (Toyokuni 1999). Acute inflammatory reactions, such as those
seen in ischemia-reperfusion and CS, are mediated by a number of pro-inflammatory
cytokines (Donohoe 2015). Cytokines are known to induce oxidative stress, leading to
cellular membrane compromise, changes in internal protein structure and downstream
effects on enzymes (Sprague and Khalil 2009). Interestingly, previous research has
shown that EHP leads to an upregulation of cytokine levels in various cell types, such as
periodontal ligament cells (Yamamoto, Kita et al. 2006), bladder smooth muscle cells
(Liang, Xin et al. 2016), mesenchymal stem cells (Becquart, Cruel et al. 2016), human
tumour cells (Fucikova, Moserova et al. 2014) and human chondrocytes (Fioravanti,
Moretti et al. 2007). It has been demonstrated, using vascular endothelial cells, that an
increase in intraluminal pressure leads to an induction of nuclear factor кB (NF- кB)
(Lemarie, Esposito et al. 2003), a transcription factor controlling the expression of
various cytokines, chemokines and adhesion molecules (De Martin, Hoeth et al. 2000). In
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addition, application of cyclic hydrostatic pressure to HUVECs found an increase in
CD95, a member of the TNF receptor family that is known to induce apoptosis, as well as
elicit cytokine release (Hasel, Durr et al. 2005).
In addition to activation of the pro-inflammatory pathways, ROS also play a
critical role in activation of various caspases (e.g. caspase-3), cytosolic enzymes
responsible for the induction of cell apoptosis (Elmore 2007). In the current study, EHP
resulted in an increase in endothelial apoptosis (Figure 2.4). This is consistent with the
observations of Ju et al. (2009), who found that an exposure of cultured retinal ganglion
cells to EHP of 30mmHg led to mitochondrial fissuring and increased release of
cytochrome c into the cytoplasm, thus activating caspase-3 (Ju, Kim et al. 2009).
Additionally, Lee et al. (2010) also found an increase in intracellular calcium elevation
followed by elevated caspase-3/7 activation, suggesting that calcium, through its impact
on ion channel activity and water efflux, is responsible for signalling the onset of the
apoptotic cell changes (Lee, Lu et al. 2010). Given that CS produces a strong pro-oxidant
and pro-inflammatory environment (characterized by the presence of ROS and
inflammatory cytokines, particularly TNF-α (Lawendy, Bihari et al. 2014, Lawendy,
Bihari et al. 2015)) it is plausible to assume that, in response to EHP, both intrinsic
(mitochondria/cytochrome c-mediated) and extrinsic (TNF-α receptor-mediated)
apoptotic pathways would be activated (Elmore 2007).
One of the essential features of CS appears to be the production of proinflammatory mediators, and subsequent infiltration of activated leukocytes, particularly,
neutrophils, into the affected tissue (Sadasivan, Carden et al. 1997, Lawendy, Sanders et
al. 2011). Leukocyte activation, recruitment and accumulation at the site of injury are
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normal host responses intended to assist with pathogen and dead cell removal. However,
in pathological situations, response to cellular stress, the accumulation of PMNs and
subsequent production of cytotoxic ROS, coupled with a release of proteolytic enzymes
can overwhelm the system, thus contribute to the parenchymal damage. Activated
leukocytes, and the pro-inflammatory state they create will impair the viability of
surrounding cells (Toyokuni 1999), further contributing to tissue injury and organ
dysfunction.
Recent research indicates that the pathophysiology underlying CS is, at least in
part, driven by ischemia-reperfusion injury. The cellular and clinical effects of complete
ischemia on the skeletal muscle are well documented (Harman 1948, Strock and Majno
1969, Labbe, Lindsay et al. 1987, Belkin, Brown et al. 1988, Lindsay, Liauw et al. 1990,
Hickey, Hurley et al. 1992, Sabido, Milazzo et al. 1994): ischemia creates a shift in
cellular metabolism towards a mainly oxidative mode, while restoration of previously
ischemic tissue will produce a pro-inflammatory state (Gute, Ishida et al. 1998, Gillani,
Cao et al. 2012), characterized by an influx of activated leukocytes from the circulation
into the surrounding tissues (Hernandez, Grisham et al. 1987, Kubes, Suzuki et al. 1990,
Schlag, Harris et al. 2001). PMN recruitment involves a series of complex and wellcoordinated cell-to-cell interactions by differential expression of various adhesion
molecules on both the endothelium and the leukocyte; these include selectin-mediated
PMN rolling, integrin-mediated firm adhesion, followed by PECAM-1-, CD99- and
JAM-mediated transmigration across the endothelial barrier into the interstitial space
(Ley, Laudanna et al. 2007). Furthermore, activated leukocytes themselves are also a
significant source of ROS and proteolytic enzymes, contributing to interstitial edema
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(Sexton, Korthuis et al. 1990, Forbes, Carson et al. 1995, Rubin, Romaschin et al. 1996,
Kurose, Argenbright et al. 1997, Gute, Ishida et al. 1998). In the context of CS, the fluid
accumulation leads to a significant increase in the interstitial pressure, further
compressing the neighbouring capillaries and exacerbating the perfusion deficit
(Lawendy, Sanders et al. 2011).
In the current study, EHP applied to endothelial cells led to a significant increase
in leukocyte adhesion (Figure 2.5), a key feature of leukocyte and/or vascular endothelial
cell inflammatory activation (Butcher 1991, Ley, Laudanna et al. 2007). These results
suggest that EHP not only induces ROS production, apoptosis and cytokine release, but it
also has the potential to induce endothelial cell activation directly. It is plausible to
assume that changes in hydrostatic pressure will cause changes in the expression of
adhesion molecules on the vascular endothelium (e.g. P-selectin, E-selectin, ICAM-1,
VCAM-1), allowing them to interact with their ligands on the PMNs (e.g. L-selectin,
sialyl-LewisX, β2 integrins).
In summary, this is the first study demonstrating the impact of increased
hydrostatic pressure on the human vascular endothelial cells in an in vitro model of CS. It
represents the first step in an attempt to further elaborate to mechanisms driving the
pathophysiology of CS.
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CHAPTER 3. CARBON MONOXIDE-RELEASING MOLECULE-3 (CORM-3)
IMPROVES ENDOTHELIAL CELL DYSFUNCTION IN AN IN VITRO MODEL
OF COMPARTMENT SYNDROME

3.1 INTRODUCTION
Compartment syndrome (CS) is a devastating complication of musculoskeletal
trauma. CS occurs following a rise in intra-compartmental pressure within a closed
osseofascial compartment. If unrecognized, and/or untreated, the condition will lead to a
muscle-threatening and limb-threatening ischemia (Whitesides, Haney et al. 1975,
Matsen, Winquist et al. 1980, Mubarak and Hargens 1983). Currently, the only definitive
treatment is surgical fasciotomy, with the goal of fully decompressing all of the affected
compartments (Eaton and Green 1972, Rorabeck 1984). Fasciotomy must be carried out
within 6-8 hours of CS onset, or the resulting tissue damage, neurovascular injury and
limb ischemia become permanent.
The increase in compartmental pressure seen in CS leads to microcirculatory
compromise restricting oxygen and nutrient delivery to the tissues, thus leading to
cellular anoxia, tissue necrosis and limb dysfunction (Whitesides, Haney et al. 1975,
Hargens, Schmidt et al. 1981). However, unlike situations of complete ischemia, CS
causes tissue necrosis in the presence of patent vessels. Although the full
pathophysiology of CS has not been fully elucidated, the contribution of inflammation is
increasingly being recognized as one of the important driving forces (Lawendy, Sanders
et al. 2011, Bihari, Cepinskas et al. 2015). Lawendy et al (2011) and others (Sadasivan,
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Carden et al. 1997, Kalns, Cox et al. 2011) have shown that leukocytes appear to play an
important role in producing both the microvascular and the parenchymal injury seen in
CS.
Unfortunately, there are currently a limited number of effective therapeutic
options when it comes to treating CS. Recently, carbon monoxide (CO), a byproduct of
heme oxygenase (HO) activity, has been shown to improve microvascular perfusion, and
to convey anti-inflammatory benefits during systemic inflammation. The exogenous
administration of CO via inhalation leads to increased carboxyhemoglobin (COHb)
levels, toxic to the host in the form of CO poisoning. However, transitional metal
carbonyls, such as CO-releasing molecules (CO-RMs), have been synthesized and can be
used experimentally, to deliver CO to the tissues in a controlled manner without
significantly raising COHb levels (Motterlini, Clark et al. 2002, Clark, Naughton et al.
2003). While most CO-RMs are soluble in organic solvents, carbon monoxide-releasing
molecule-3 (CORM-3) is water soluble (Motterlini and Otterbein 2010), making it an
ideal choice for clinical applications. In a rodent and porcine models of CS, the
application of CORM-3 at the time of surgical fasciotomy was shown to diminish tissue
injury, leukocyte activation and block the systemic release of TNF-α, a very potent proinflammatory cytokine (Lawendy, Bihari et al. 2014, Bihari, Cepinskas et al. 2015).
While these results are promising, more experimental testing is required before CORM-3
could be used as a therapeutic agent in human patients. Furthermore, the underlying
mechanism and the actual beneficial effects of CORM-3 protection, as well as its
potential side effects still remain to be elucidated.
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The primary purpose of this study was to provide a transition between the
previous animal studies and future testing of CO on human subjects. We attempted to
evaluate the relative contribution of both elevated tissue pressure and inflammation to the
pathophysiology of CS, as well as to examine the beneficial effect of CORM-3-derived
CO. To this end, we used two clinically relevant in vitro models of CS: elevation of
hydrostatic pressure (EHP) and the exposure of human vascular endothelial cells
(HUVECs) to a cytokine/chemokine cocktail (representing the serum levels of
inflammatory mediators previously detected in our experimental animal models of CS)
(“CS cocktail”) (Donohoe 2015). We hypothesized that the exposure of endothelial
monolayer to inflammatory cytokines/chemokines will result in similar response to that
obtained by the application of EHP, characterized by the activation of the endothelium,
endothelial barrier breakdown and dysfunction. In addition, given that CORM-3 appears
to provide beneficial effects in various animal models (Bihari 2017), we surmised that we
could replicate these results in vitro, and also explore some of the mechanisms through
which CORM-3 protects the endothelium. The ultimate goal of this research is the
development of a safe pharmacologic adjunct therapy aimed at human patients with CS,
in order to reduce the morbidity and disability resulting from this devastating condition.

3.2 MATERIALS AND METHODS
3.2.1 Reagents
Medium-199 (M199), fetal bovine serum, penicillin, streptomycin and Dulbecco’s
PBS (DPBS) (pH 7.4) were purchased from Invitrogen Canada (Life Technologies Inc.,
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Burlington, ON). Dihydrorhodamine (DHR)-123 was obtained from Molecular Probes
Inc. (Eugene, OR). Human recombinant TNF-α, IL-1β and GRO were purchased from
Invitrogen Canada (Life Technologies Inc., Burlington, ON). A water-soluble CORM-3
(tricarbonylchloro-glycinate-ruthenium(II), [Ru(CO)3Cl-glycinate]; molecular weight 295
gmol-1) was synthesized by this laboratory (Mizuguchi, Stephen et al. 2009), in
accordance with the previously-published method (Motterlini, Clark et al. 2002).
CORM-3 (100µM stock solution) was always prepared fresh by dissolving CORM-3 in
M199 just prior to use. Inactive CORM-3 (iCORM-3) was generated by leaving CORM3 solution for 72hrs at room temperature, to liberate all CO from the molecule, as
previously described (Clark, Naughton et al. 2003).

3.2.2 Cells
Human vascular endothelial cells (HUVECs), isolated from human umbilical
veins by collagenase treatment (Cepinskas, Savickiene et al. 2003), were grown to
confluence on fibronectin-coated cellware (12-well plates, transwell inserts with 1µm
diameter pores, 96-well plates and parallel-flow perfusion microslides). HUVECs at
passages 1-3 were used for all of the experiments.
Human neutrophils (PMNs) were isolated from the venous blood of healthy adults
by 1% Dextran (Sigma, Mississauga, ON) sedimentation and gradient separation on
Histopaque-1077 (Sigma, Mississauga, ON), as previously described (Kuhns, Long Priel
et al. 2015). PMN viability was confirmed by Trypan blue dye exclusion test.
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3.2.3 In vitro Models of CS
To assess the relative contribution of physical tissue pressure elevation versus
pro-inflammatory conditions to the severity of tissue injury seen in CS, two different
models were employed: elevation of hydrostatic pressure (EHP), and cytokine/chemokine
cocktail stimulation.

3.2.3.1 Elevation of Hydrostatic Pressure
Confluent HUVECs were exposed to EHP of 30mmHg, obtained via a gravity-fed
system, for 6 hours, as previously described (Chapter 2, Figure 2.1). The system was
connected to a compartment pressure monitor (Synthes, Westchester, PA) to ensure that
constant and uniform pressures were obtained for the duration of the experiment.
Cells exposed to the same environmental conditions (i.e. 37°C, 5%CO2) but
normal pressure (0mmHg), served as a control for all experimentation.

3.2.3.2 Cytokine Cocktail Stimulation
Confluent HUVECs were stimulated with a cytokine/chemokine cocktail
representing the serum levels of inflammatory mediators previously detected in our
experimental model of CS (“CS cocktail”) (Donohoe 2015) (Table 3.1) for 6 hours. The
CS cocktail contained human recombinant TNF-α (1ng/ml), IL-1β (100pg/ml) and GRO
(1ng/ml).
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3.2.4 Reactive Oxygen Species (ROS) Production
The production of ROS in HUVECs was measured by intracellular oxidation of
DHR-123, a pan-oxidant-sensitive fluorochrome, as previously described (Mizuguchi,
Stephen et al. 2009). HUVECs (1x106 cells), grown to confluence in 12-well fibronectincoated plates, were loaded with DHR-123 (10µM) for 45min, and then subjected to either
EHP of 30mmHg or stimulation with CS cytokine cocktail, for 6 hours, in the presence of
CORM-3, or its inactive counterpart, iCORM-3. After stimulation, cells were washed
with PBS, lysed in 0.5% CHAPS buffer and analysed spectrofluorometrically (FR-1501
spectrofluorometer, Shimadzu) at excitation/emission wavelengths of 495/523nm. Protein
concentration in the cell lysate was assessed by DC protein assay (BioRad, Mississauga,
ON). ROS production was expressed as DHR-123 fluorescence intensity (FI) per mg
protein.

3.2.5 Measurement of the Endothelial Monolayer Integrity
HUVECs were grown to confluence on fibronectin-coated transwell inserts (1µm
diameter pores) (BD Falcon). Cells were subjected to 6 hours of either EHP of 30mmHg,
or stimulation with CS cytokine cocktail, in the presence of CORM-3 (or iCORM-3). The
integrity of the endothelial layer was assessed by measuring the transendothelial
electrical resistance (TEER) using EndOhm chamber method (EndOhm-6, World
Precision Instruments) following 1hr, 3hr and 6hr EHP or CS cytokine cocktail exposure,
and expressed as Ωcm2. Changes in TEER from the baseline were evaluated at each time
point.
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Table 3.1

Serum levels of cytokines/chemokines detected in a rat model of CS.
Twenty-four different cytokines and chemokines were tested; those with
detectable values are shown here. Cytokines showing significant
upregulation in response to CS were utilized to model CS in vitro.
*p<0.05.

Cytokine/Chemokine

Baseline

CS

Fold
change

p-value

(pg/ml)

(pg/ml)

Eotaxin

228.0±161.3

175.7±144.3

-0.2

0.4431

TNF-a

33.7±6.8

1223.1±483.0*

36

0.0002

IL-1a

473.9±291.7

434.7±179.3

-0.1

0.8887

IL-1b

47.9±35.7

141.3±18.6*

3

0.0481

MIP-1a

69.8 ±66.4

84.8±41.0

0.2

0.7012

MCP-1

313.4±35.1

399.6±42.4

0.3

0.8737

GRO/KC

990.2±213.3

2984±1310*

3

0.0194

IFN-¡

326.6±98.6

360.4±159.3

0.1

0.8463

Leptin

9596±1038

8606±1353

-0.1

0.5344

IL-6

2566±1758

2351±1494

-0.1

0.9084

IL-13

225.3±60.0

254.9±106.9

0.1

0.7161

IL-12p70

196.1±68.1

199.2±83.5

0

0.9718

IL-18

86.6±7.3

76.4±6.1

-0.1

0.1621

IP-10

145.4±108.6

155.7±108.9

0.1

0.9424

1673±250

1680±193

0

0.3560

RANTES

102
3.2.6 Quantification of Apoptosis
HUVECs grown on black fibronectin-coated 96-well plates with clear bottom
(Greiner Bio-One) were subjected to either EHP of 30mmHg or stimulation with CS
cytokine cocktail, for 6 hours, in the presence of CORM-3 (or iCORM-3). Levels of the
activation of active caspases were assessed by FAM-FLICA poly caspase apoptosis kit
(Immunochemistry Technologies, LLC), as per manufacturer’s instructions. Briefly, cells
were incubated with FAM-FLICA poly caspase reagent for one hour at 37°C, washed and
immediately assessed for fluorescence using Victor-3 plate reader (Perkin-Elmer), at
excitation/emission wavelengths of 480nm/530nm. Levels of apoptosis were expressed as
relative fluorescence units (RFU) (i.e. fluorescence intensity/104).

3.2.7 PMN Rolling/Adhesion Assay
HUVECs grown on the parallel-flow perfusion microslides (µ-slide VI0.4; ibidi,
Madison, WI) were subjected to either EHP of 30mmHg or stimulation of with CS
cytokine cocktail, for 6 hours, in the presence of CORM-3 (or iCORM-3). Following this,
microslides with HUVECs were placed into an air-heated chamber (37°C) attached to an
inverted phase-contrast microscope (Diaphot 300, Nikon). After 10min wash with M199
in the presence of CORM-3 or iCORM-3 at a shear stress of 1dyn/cm2 obtained by
syringe pump (Harvard Apparatus, St. Laurent, QC), PMNs (1x106/ml) isolated from
healthy adult volunteers were added to the perfusion medium, and the perfusion was
continued for 15 minutes at the same shear stress. PMN-HUVECs adhesive interactions
(i.e. rolling, adhesion) were captured in six random fields of view (10s/field) with a
digital CCD camera (Sony Corp., Japan) connected to a computer, and analyzed offline.
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PMNs with velocity less than 100µm/s were considered “rolling”. Adhesion was defined
as PMNs that remained stationary for at least 10s. PMN rolling/adhesion were expressed
as a number of PMN/mm2.

3.2.8 Statistical Analysis
All parameters were expressed as means ± standard error of the mean (SEM), and
analyzed using two-way analysis of variance (ANOVA) (GraphPad Prism, v. 5.0, San
Diego, CA), with Bonferroni post-hoc test as needed. p<0.05 was considered statistically
significant. All experiments were repeated four times (on 4 different days), to account for
variability in ambient environmental factors.

3.3 RESULTS
3.3.1 ROS Production
Exposure of HUVECs to EHP, or their incubation with CS cytokine cocktail
induced a significant increase in the production of ROS, as shown in Figure 3.1. DHR123 fluorescence intensity increased from 578.0±43.4.5 FI/mg protein in unstimulated
control cells to 791.5±64.4 and 1169.1±155.8 Fl/mg protein in cells exposed to EHP or
CS cytokine cocktail, respectively (p<0.05). CORM-3 treatment significantly decreased
ROS production in both the EHP and the CS cytokine cocktail groups, to 516.8±48.0 and
468.3±37.8 Fl/mg protein, respectively (p<0.05), while it had no effect on the
unstimulated control endothelial cells (Figure 3.1).
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Figure 3.1

Control

EHP

Cytokine Cocktail

The effect of CORM-3 on the oxidative stress response in human
vascular endothelial cells in an in vitro model of CS. HUVECs were
subjected to 6 hours of sustained 30mmHg EHP or cytokine cocktail
stimulation in the presence of CORM-3 (or iCORM-3), and the levels of
ROS production were assessed by DHR-123 assay (two-way ANOVA,
p<0.05, *p<0.05 from Control, †p<0.05 from EHP+iCORM-3 and
Cytokine Cocktail+iCORM-3, N=4 per group).
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3.3.2 Transendothelial Electrical Resistance (TEER)
Exposure of HUVECs to EHP led to a gradual decrease in the integrity of the
endothelial monolayer, as indicated by a decrease of TEER from the baseline of
63.4±3.3Ωcm2 to 48.6.5±4.3Ωcm2, 38.7±3.2Ωcm2 and 35.3±3.5Ωcm2 at 1hr, 3hr and 6hr
EHP, respectively (p<0.05). Incubation of HUVECs with cytokine cocktail produced a
gradual decrease in TEER to 24.5±7.0Ωcm2, 16.1±7.1Ωcm2 and 13.6±6.2Ωcm2 at 1hr,
3hr and 6hr exposure, respectively (p<0.05 from control) (Figure 3.2).
CORM-3 treatment of cells exposed to EHP significantly diminished the
magnitude of changes in TEER to 52.0±5.0Ωcm2, 52.1±2.3Ωcm2 and 47.0±3.2Ωcm2 at
1hr, 3hr and 6hr, respectively (p<0.05 from EHP+iCORM-3). In parallel, CORM-3
treatment of cells stimulated with CS cytokine cocktail significantly diminished the
magnitude of changes in TEER to 44.4±3.0Ωcm2, 44.2±4.4Ωcm2 and 39.5±8.7Ωcm2 at
1hr, 3hr and 6hr, respectively (p<0.05 from CS cytokine cocktail+iCORM-3) (Figure
3.2).

3.3.3 Apoptosis
Exposure of HUVECs to EHP, or incubation with the CS cytokine cocktail led to
a significant increase in the activation of caspases, as shown in Figure 3.3. Apoptosis
increased from 2.4±0.1 RFU in control to 8.8±0.4 RFU in EHP and 10.3±1.0 RFU in
cytokine cocktail groups (p<0.05). CORM-3 treatment significantly decreased the
activation of caspases to 4.0±0.4 RFU in cytokine cocktail group (p<0.05), while having
no effect on caspases activity in EHP group (8.6±0.3 RFU, n.s.) (Figure 3.3). CORM-3 or
iCORM-3 had no effect on the activity of caspases in control cells.
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Figure 3.2

The effect of CORM-3 on the integrity of human vascular endothelial
cell monolayer in an in vitro model of CS. HUVECs were subjected to 6
hours of sustained 30mmHg EHP, or cytokine cocktail stimulation, in the
presence of CORM-3 (or iCORM-3), and the integrity of monolayer was
assessed by measuring the transendothelial electrical resistance (TEER)
(two-way repeated measures ANOVA, p<0.05, *p<0.05 from Control,
†p<0.05 from Cytokine Cocktail+iCORM-3, #p<0.05 from EHP+iCORM3, N=3 per group).
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The effect of CORM-3 on the level of apoptosis in human vascular
endothelial cells in an in vitro model of CS. HUVECs were subjected to
6 hours of sustained 30mmHg EHP or cytokine cocktail stimulation in the
presence of CORM-3 (or iCORM-3), and the levels of active caspases
were assessed by FAM-FLICA (two-way ANOVA, p<0.05, *p<0.05 from
Control, †p<0.05 from Cytokine Cocktail+iCORM-3, N=4 per group).
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3.3.4 Leukocyte Activation
Exposure of HUVECs to EHP resulted in a marked increase in PMN activation,
from 0.4±0.3 rolling PMNs/0.1mm2 and 4.0±1.5 adherent PMNs/0.1mm2 in control to
2.2±0.6 rolling PMNs/0.1mm2 and 12.8±1.8 adherent PMNs/0.1mm2 in EHP group
(p<0.05) (Figure 3.4). Incubation of HUVECs with the CS cytokine cocktail resulted in a
significant increase in PMN activation to 2.1±0.3 rolling PMNs/0.1mm2 and 21.0±4.5
adherent PMNs/0.1mm2 (p<0.05) (Figure 3.4).
CORM-3 treatment of HUVECs exposed to EHP did not have significant effect .
with 1.5±0.5 rolling PMN/0.1mm2 and 8.0±1.5 adherent PMN/0.1mm2. CORM-3
treatment of HUVECs exposed to CS cytokine cocktail resulted in a significant decrease
in PMN activation to 0.5±0.1 rolling PMN/0.1mm2 and 4.4±0.7 adherent PMN/0.1mm2
(p<0.05) (Figure 4.4). There was no difference in PMN rolling or adhesion in
unstimulated control HUVECs between the CORM-3 and iCORM-3 groups.

3.4 DISCUSSION
CS is associated with significant morbidity and patient disability (Giannoudis,
Nicolopoulos et al. 2002) and often poses a significant clinical challenge for the
physician and surgical team. Currently, the gold standard for definitive management of
CS is surgical fasciotomy, with few other proven adjuncts (Olson and Glasgow 2005).
While some supportive therapies have shown limited success in animal models (Manjoo,
Sanders et al. 2010, Lawendy, Bihari et al. 2014), their use is hindered by the lack of
understanding the full underlying pathophysiological basis of CS.
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The effect of CORM-3 on leukocyte (A) rolling and (B) adhesion in
response to EHP, or cytokine cocktail stimulation of human vascular
endothelial cells in an in vitro model of CS. HUVECs were subjected to
6 hours of sustained 30mmHg EHP, or cytokine cocktail stimulation, in
the presence of CORM-3 (or iCORM-3), followed by application of naïve
PMNs, while being superfused at a constant rate of 1dyn/cm2 (two-way
ANOVA, p<0.05, *p<0.05 from Control, †p<0.05 from Cytokine
Cocktail+iCORM-3, N=4 per group).
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CS is a complex pathophysiological process, leading to upregulation proinflammatory phenotype, followed by subsequent interactions between vascular
endothelial cells and activated leukocytes. This leads to impaired vascular cell integrity,
increased vascular permeability and leukocyte extravasation, followed by the clinical
appearance of edema (Sabido, Milazzo et al. 1994). The production of pro-inflammatory
mediators, coupled with leukocyte accumulation within the affected organ, is one of the
key features of CS. While leukocyte recruitment at the site of injury is a normal
physiological response, the overwhelming recruitment of PMNs, with the subsequent
release of cytotoxic ROS and proteolytic enzymes, further exacerbates the parenchymal
damage already seen in CS. Activated leukocytes are known to impair surrounding cell
viability (Toyokuni 1999), further contributing to the already existing tissue injury and
dysfunction.
Recent findings indicate that exogenous application of CO has potent antiinflammatory effects (Motterlini and Otterbein 2010). However, inhalation of CO may
lead to the formation of toxic levels of COHb (i.e. >10%), thus limiting its clinical use
(Ryter, Alam et al. 2006, De Backer, Elinck et al. 2009). In order to address this, COreleasing molecules (CO-RMs) - transitional metal carbonyls that can release CO on
demand - have been synthesized. CO-RMs allow for CO delivery to the tissues without
the associated rise in COHb and offer various routes of administration (IV, IP, SC or
tissue superfusion) (Motterlini, Mann et al. 2005). Multiple studies have shown beneficial
anti-inflammatory effects of CO-RMs: ischemia/reperfusion injury (Katada, Bihari et al.
2010), pulmonary hypertension (Zuckerbraun, Chin et al. 2006), organ transplant (Song,
Kubo et al. 2003) and sepsis (Cepinskas, Katada et al. 2008).
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Currently, there is a dearth of knowledge when it comes to understanding the role
of CO-RMs on modulation of the response seen in CS, as well as the changes
experienced at the cellular and molecular levels. Recently, we developed and tested a
relevant experimental animal models of CS (Lawendy, Sanders et al. 2011, Bihari 2017).
The studies found that CORM-3 had a significant therapeutic impact by reducing the
inflammatory response and the resulting tissue injury, while preserving microvascular
perfusion (Lawendy, Bihari et al. 2014, Bihari 2017). However, there are currently no
human patient studies which have evaluated the role of elevated hydrostatic pressure, or
the response to CORM-3 in CS.
In the present study, we attempted to mimic the CS conditions in vitro, by
utilizing human vascular endothelial cells and two clinically-relevant CS stimuli, in order
to examine the relative contribution of physical changes associated with EHP or
cytokine-induced inflammation to the pathophysiology of CS, as well as to determine
how CORM-3 offers protection upon exposure to these stimuli. To our knowledge, this is
the first studies to model CS in such manner in humans.
Exposure of HUVECs to EHP resulted in a significant increase in intracellular
production of ROS (Figure 3.1). This can most likely be linked to changes in the
mitochondrial respiratory chain (Wang, Guerrero et al. 2015), and upregulation of
downstream signalling molecules, which in turn, triggers inflammation (Toyokuni 1999).
In addition, incubation of HUVECs with CS cytokine cocktail also resulted in a similar
response; the data is consistent with prior research findings in CS and ischemiareperfusion injury (Zhang, Hu et al. 2005, Cavaillon and Annane 2006, Lawendy, Bihari
et al. 2014, Lawendy, Bihari et al. 2016). Cell stimulation by cytokines is known to
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induce oxidative stress, leading to compromise of the cellular membrane, intercellular
junctions and internal protein structures (Sprague and Khalil 2009). Our previous
findings indicate that EHP also leads to significant stress fiber formation, changes in in Factin and VE-cadherin expression, leading to a breakdown of endothelial barrier
(Acevedo, Bowser et al. 1993, Tokuda, Miyazaki et al. 2009, Cao, Xia et al. 2015).
Increased oxidative stress, through ROS-based signalling, also leads to alterations
in endothelial cell cytoskeleton and adherence junctions (Corada, Liao et al. 2001). In
addition, previous reports found that EHP leads to an upregulation of cytokine levels in
various cell types, such as periodontal ligament cells, bladder smooth muscles cells,
mesenchymal stem cells, human tumour cells and human chondrocytes (Yamamoto, Kita
et al. 2006, Fioravanti, Moretti et al. 2007, Fucikova, Moserova et al. 2014, Becquart,
Cruel et al. 2016, Liang, Xin et al. 2016). The effect occurs through the upregulation of
various downstream transcription factors, resulting in increased expression of various
chemokines and cytokines (De Martin, Hoeth et al. 2000).
In our experiments, application of CORM-3 (but not iCORM-3) was able to
diminish ROS release in both the EHP and cytokine cocktail stimulation groups. It has
been demonstrated that there is a significant cross-talk between ROS and various
enzymes, such as matrix metalloproteinases (MMP) and cell surface membrane proteins
(various integrins) (Svineng, Ravuri et al. 2008). In addition, it has been shown that EHP
is able to modulate various cellular pathways, including the induction of MMP (Inoue,
Arai et al. 2015). Interestingly, previous studies found that exogenous application of CO,
in the form of CORM-2, was able to diminish the induction of MMP expression and its
downstream effects (Tsai, Lee et al. 2017). These reports further support the notion that
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the protective effect of CORM-3 is likely mediated through its effects on downstream
transcription factors, upregulated by both the direct effect of EHP and the presence of
various inflammatory cytokines.
Exposure of human endothelial cells to EHP or CS cytokine cocktail led to a
significant breakdown of the endothelial barrier, evidenced by a decrease in transendothelial electrical resistance (Figure 3.2). Previously, EHP has been found to lead to
changes in endothelial cell morphology and diffusion barrier characteristics in multiple
cell types (Acevedo, Bowser et al. 1993, Ohashi, Sugaya et al. 2007, Tokuda, Miyazaki et
al. 2009, Cao, Xia et al. 2015). Cellular permeability and leukocyte extravasation are
controlled by adhesive interactions between various endothelial cell surface proteins
(Ley, Laudanna et al. 2007). EHP appears to not only have an effect on cell-cell
junctions, but it also affects the upregulation of adhesion molecules that are involved in
microvessel integrity, as demonstrated by a rapid decrease in TEER, correlated with a
transient loss and/or redistribution of PECAM-1 (Sharma, Templin et al. 2013,
Souvannakitti, Peerapen et al. 2016). CORM-3 treatment preserved endothelial
monolayer integrity; a plausible explanation being that CORM-3 can modulate F-actin
expression/distribution and various transcription pathways (particulary MAPK) (Inoue,
Patterson et al. 2017). Another possibility is that CORM-3 may modulate mitochondriabased pathways. Previous reports have found EHP leads to mitochondrial fission and a
reduction in cellular ATP (Ju, Liu et al. 2007); CORM-3 has been shown to uncouple
mitochondrial respiration and activate phosphate carriers, enhancing mitochondrial
phosphate uptake (Long, Salouage et al. 2014). Additionally, CORM-3 also appears to
have a significant impact on membrane potential and permeability, through its effects on
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the transmembrane movement of K+ and Na+, causing changes in cellular respiration and
H+ pumping (Wilson, Jesse et al. 2013).
Treatment of endothelial cells with EHP or CS cytokine cocktail resulted in a
significant increase in caspase activation. Surprisingly, while CORM-3 treatment
prevented apoptosis in the CS cytokine cocktail group, it had no effect on apoptosis
levels in the cells exposed to EHP. Increased oxidative stress, through ROS-based
signalling (Toyokuni 1999), plays an important role in caspase activation and eventual
apoptosis (Elmore 2007). Multiple studies, both in vivo and in vitro, have demonstrated
the anti-apoptotic effects of CO (Brouard, Otterbein et al. 2000, Petrache, Otterbein et al.
2000, Bihari, Cepinskas et al. 2014, Lawendy, Bihari et al. 2014). In the clinical and
experimental scenario, elevated intracompartmental pressure leads to a significant rise in
the inflammatory cytokine TNF- α (Lawendy, Bihari et al. 2015, Lawendy, Bihari et al.
2016, Bihari 2017) which is an important mediator of apoptosis via modulation of the
expression of various proteolytic caspases (Seekamp, Warren et al. 1993, Roebuck,
Carpenter et al. 1999, Ley 2008). Previously, treatment with CORM-3 has been shown to
lead to a significant decrease in circulating TNF-α levels (Cepinskas, Katada et al. 2008,
Lawendy, Bihari et al. 2014, Donohoe 2015, Bihari 2017). Heme oxygenase inhibitors
have also been shown to lead to a significant decrease in TNF-α-induced apoptosis in an
in vitro model of both mouse fibroblasts and endothelial cells (Petrache, Otterbein et al.
2000). In our study, the lack of CORM-3 effect upon exposure of HUVECs to EHP could
be due to a relatively high dose of CORM-3 delivered to the HUVECs, changing its
relative effect. In several experimental models of disease and/or tissue injury such as
ischemia-reperfusion and lung transplantation, pre-treatment with low dose CO led to a
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net anti-apoptotic effect (Ryter, Alam et al. 2006), although higher concentrations of CO
produced pro-apoptotic effects (Piantadosi, Zhang et al. 1997). In addition, apoptotic
effects of EHP have been shown to be time dependent (Hasel, Durr et al. 2005); it is
plausible to assume that the lack of response to CORM-3 could have been due to time
dependent changes in activated caspase levels.
The exposure of endothelial cells to EHP or CS cytokine cocktail led to a
significant increase in leukocyte adhesive interactions (Figure 3.4), which remains a key
feature of leukocyte and/or vascular endothelial cell inflammatory activation (Butcher
1991, Ley, Laudanna et al. 2007). The process is mediated by various cytokines,
chemokines and cell surface proteins on the activated endothelial cells (Albelda, Muller
et al. 1991). Changes in hydrostatic pressure are likely to directly cause alterations in the
expression of adhesion molecules on the vascular endothelium (e.g. P-selectin, E-selectin,
ICAM-1, VCAM-1), allowing them to interact with their ligands on the PMNs (e.g. Lselectin, sialyl-LewisX, β2 integrins).
CORM-3 treatment was able to inhibit both leukocyte adhesion and rolling
(Figure 3.4) in the cytokine cocktail group, but the beneficial effects were not reproduced
in the EHP group. Previously, the application of CORM-2 significantly reduced levels of
vascular endothelial adhesion molecules such as E-selectin and ICAM-1 (Nizamutdinova,
Kim et al. 2009, Katada, Bihari et al. 2010). A decrease in E-selectin and VCAM-1
expression has also been shown by pre-treatment with CORM-3 in HUVECs (Song,
Bergstrasser et al. 2009). These results however, have not been universally found, as
other studies have failed to show the ability of CORM-3 to suppress vascular endothelial
cell adhesion protein expression (Urquhart, Rosignoli et al. 2007). Perhaps the lack of

116
statistically significant response in the EHP group following exposure to CORM-3 may
be explained by its relative abilities to modulate adhesion on the endothelium when
compared to the activated leukocytes. Although the effects of CORM-3 have been shown
to modulate adhesive interactions on both activated leukocytes and the endothelium, its
effect may be more significant on the former (Urquhart, Rosignoli et al. 2007).
To our knowledge, this is the first study demonstrating the beneficial effects of
carbon monoxide, delivered in the form of CORM-3, in two clinically relevant human in
vitro models of CS. While the exact mechanisms of CORM-3 protective action remain to
be determined, the obtained data helps translate previous animal model research to
human trials, and suggests a potential therapeutic application of CORM-3 in CS.
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CHAPTER 4. GENERAL DISCUSSION AND CONCLUSIONS

4.1 OVERVIEW OF RESULTS
CS is a true medical and surgical emergency associated with potentially
devastating complications. Currently, the only proven treatment is surgical fasciotomy, to
decompress all involved osseofascial compartments. The procedure, however, is
associated with relatively frequent and significant complications leading to patient
morbidity and dysfunction (Whitesides, Hirada et al. 1977). Certain adjunct and
supportive therapies have shown limited therapeutic potential in various animal models
(Manjoo, Sanders et al. 2010, Lawendy, Bihari et al. 2014, Bihari 2017), but their use in a
clinical setting is hindered by our current lack of understanding of the underlying
pathophysiology of CS, as well as their method of action. Recent reports utilizing animal
models of CS have shown that unlike complete ischemia, CS creates a microcirculatory
“low flow” environment, occurring in the presence of patent arterial vessels. This leads to
early significant leukocyte activation, which in turn further contributes to parenchymal
injury, cellular ischemia and limb dysfunction (Lawendy, Sanders et al. 2011).
CO has emerged as an important mediator of cell signalling while also possessing
anti-ischemic, anti-oxidant, anti-inflammatory, anti-apoptotic and vasodilatory properties
(Kim, Ryter et al. 2006). In order to clinically utilize the beneficial attributes of this gas, a
novel class of transition metal carbonyls capable of releasing CO on demand, the carbon
monoxide-releasing molecules (CO-RMs), was experimentally synthesized (Motterlini,
Clark et al. 2002). CO-RMs are capable of delivering safe levels of CO to the tissues in a
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controlled manner, without causing a corresponding dangerous rise in COHb (Motterlini,
Clark et al. 2002).
Recent studies using animal models of CS (rat and pig) found that the
administration of CORM-3 at the time of fasciotomy was associated with a decrease in
leukocyte activation, systemic TNF-α release and diminished tissue injury, while
improving microvascular perfusion (Lawendy, Bihari et al. 2014, Bihari 2017), but it has
never been tested in human patients. In vitro modelling of CS allows to not only explore
the underlying pathophysiology in a mechanistic manner, but also permits the
development and testing of interventions (e.g. CO-RMs) that are currently not possible
(or unethical) in humans. The goal of this thesis was to develop and test a relevant in
vitro model of CS, using human cells, in order to expand our understanding of CS
pathophysiology, as well as the development a safe medical adjunct (or standalone
therapy) for patients presenting with CS.

4.1.1 EHP As an In Vitro Model Of CS
In Chapter 2, an attempt was made to mimic the CS conditions in vitro by
subjecting human vascular endothelial cells (HUVECs) to the CS-relevant stimulus, in
the form of elevated hydrostatic pressure (EHP), directly assessing cellular response,
while attempting to clarify the role that EHP contributes to the endothelial activation and
pro-inflammatory potential of CS. We found that exposure of HUVECs to EHP led to a
rearrangement of endothelial monolayer, characterized by

significant stress fiber

formation, as evidenced by changes in F-actin and VE-cadherin expression. Cells
exposed to EHP also experienced a significant increase in intracellular production of
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ROS, most likely due, at least in part, to changes in the mitochondrial respiratory chain
and the inner mitochondrial membrane. It can also be surmised that this increase in ROS
would then go on to trigger downstream signalling molecules, further stimulating
inflammation (Toyokuni 1999).
EHP applied to endothelial cells also led to a significant increase in leukocyte
adhesion, a key feature of leukocyte and/or vascular endothelial cell inflammatory
activation (Butcher 1991, Ley, Laudanna et al. 2007). These results suggest that EHP not
only induces ROS production and apoptosis, but it also directly promotes endothelial cell
activation. Changes in hydrostatic pressure most likely influence the transcription and
expression of adhesion molecules on the vascular endothelium (e.g. P-selectin, E-selectin,
ICAM-1, VCAM-1), which then allows the endothelium to interact with their ligands on
the PMNs (e.g. L-selectin, sialyl-LewisX, β2 integrins), leading to increased endothelial
permeability, extravasation, and in vivo, tissue edema and parenchymal injury. Thus, our
study demonstrated that direct physical effects caused by elevated hydrostatic pressure
within the injured limb also significantly contribute to the pathophysiology of CS.

4.1.2 Effect of CORM-3
In Chapter 3, we attempted to build on our results, by testing the effect of CORM3 on HUVECs exposed to elevated hydrostatic pressure, and compare the findings to the
results obtained by CS cytokine cocktail stimulation. We studied the effects of CORM-3
on ROS production, endothelial monolayer integrity, apoptosis and endothelial activation
(leukocyte adhesion/rolling).
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Application of CORM-3 was able to decrease intracellular ROS production in
both the EHP and cytokine cocktail groups. In addition, CORM-3 also prevented the
hydrostatic pressure-induced decrease in endothelial monolayer integrity, most likely by
modifying EHP-induced cytoskeletal changes in F-actin or VE-cadherin. Surprisingly,
while CORM-3 prevented apoptosis in the CS cytokine cocktail group, it had no effect on
the level of apoptosis in the cells exposed to EHP, despite multiple studies previously
demonstrating the anti-apoptotic effects of CO (Brouard, Otterbein et al. 2000, Petrache,
Otterbein et al. 2000, Bihari, Cepinskas et al. 2014, Lawendy, Bihari et al. 2014).
Both EHP and CS cytokine cocktail stimulation led to a significant endothelial
activation, as demonstrated by an increase in leukocyte rolling and adhesion to the
endothelial monolayer. CORM-3 treatment was able to inhibit this response in the CS
cytokine cocktail group but did not have a similar effect in the hydrostatic pressure
group. The difference in magnitude could be explained by the ability of CORM-3 to
modulate the expression of various adhesion molecules on both activated leukocytes and
the endothelium, with the effect being more significant on the former (Urquhart,
Rosignoli et al. 2007).

4.2 LIMITATIONS AND FUTURE DIRECTIONS
Although we were able to demonstrate detrimental consequences of elevated
hydrostatic pressure on endothelial cells, and the beneficial effects of CORM-3 in this
novel in vitro human CS model, there were several limitations to these studies. We
arbitrarily chose to expose HUVECs to a hydrostatic pressure of 30mmHg, as this level is
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clinically relevant and feasible in the laboratory setting using a gravity-fed system.
However, the ideal pressure to which HUVECs should be exposed to in order to mimic
CS most effectively, has yet to be discerned. In addition, we did not expose endothelial
cells to different pressure changes, which (presumably) could have led to a graded
cellular response. Furthermore, we chose 4 to 6 hours of EHP based on previous reports
and clinical relevancy; in the future, comparing longer or shorter periods of exposure may
reveal interesting results in terms of cellular response and the effects of CORM-3.
Another limitation is the fact that we used only one concentration of CORM-3,
which we based on previous related reports. However, different concentrations may
prove to be more effective, without compromising cell survival. Although the goal of
this specific model was to test the effect of elevated hydrostatic pressure on HUVEC and
the potentially protective effect of CORM-3, other compounds with anti-oxidant and antiinflammatory properties, such as taurine, N-acetyl cysteine and vitamin C could
potentially be utilized, individually or in combination.
CORM-3 is in the early experimental stage, yet its effect on CS in various animal
models has been significant. Although the purpose of our experimental design was to
examine the effect of CORM-3 on CS specifically, in the future, CORM-3 could be tested
in other conditions, such as Charcot changes in the diabetic foot. Charcot changes and
ulceration have been associated with ischemia/reperfusion, elevated cytokine levels,
reactive oxygen species, apoptosis and significant inflammatory changes (Folestad,
Alund et al. 2015, Petrova, Petrov et al. 2015); A condition which appears to share many
similarities with ischemia reperfusion and CS models and which may also respond
favourably to CORM-3 treatment.

128
4.3 CONCLUSIONS
The data in this thesis indicates that the effects of elevated hydrostatic pressure on
endothelial cells is not inconsequential, and changes in hydrostatic pressure itself
significantly contribute to the pathophysiology of CS. We demonstrated the beneficial
effects of CORM-3 in an in vitro model of CS. Although certain outcomes were
unexpected, such as the lack of the effect on caspase activation in response to CORM-3
in EHP, our results suggest CORM-3 may be of benefit to patients suffering with CS.
While the exact mechanisms of CORM-3 action remain to be elucidated, CORM-3 may
have a significant potential as a pharmacological treatment to supplement and/or replace
fasciotomy, thus avoid the devastating complications associated with CS.

4.4 REFERENCES
Bihari, A. (2017). Therapeutic application of carbon monoxide in acute limb
compartment syndrome. PhD, University of Western Ontario.
Bihari, A., G. Cepinskas, D. Sanders and A. Lawendy (2014). Carbon monoxide
releasing molecule-3 (CORM-3) diminishes the oxidative stress and leukocyte migration
across human endothelium in an in vitro model of compartment syndrome. . Orthopaedic
Trauma Association Annual Meeting. Tampa, FL.
Brouard, S., L. E. Otterbein, J. Anrather, E. Tobiasch, F. H. Bach, A. M. Choi and M. P.
Soares (2000). "Carbon monoxide generated by heme oxygenase 1 suppresses endothelial
cell apoptosis." J Exp Med 192(7): 1015-1026.
Butcher, E. C. (1991). "Leukocyte-endothelial cell recognition: three (or more) steps to
specificity and diversity." Cell 67(6): 1033-1036.
Folestad, A., M. Alund, S. Asteberg, J. Fowelin, Y. Aurell, J. Gothlin and J. Cassuto
(2015). "Offloading treatment is linked to activation of proinflammatory cytokines and
start of bone repair and remodeling in Charcot arthropathy patients." J Foot Ankle Res 8:
72.

129
Kim, H. P., S. W. Ryter and A. M. Choi (2006). "CO as a cellular signaling molecule."
Annu Rev Pharmacol Toxicol 46: 411-449.
Lawendy, A. R., A. Bihari, D. W. Sanders, R. F. Potter and G. Cepinskas (2014). "The
severity of microvascular dysfunction due to compartment syndrome is diminished by the
systemic application of CO-releasing molecule-3." J Orthop Trauma 28(11): e263-268.
Lawendy, A. R., D. W. Sanders, A. Bihari, N. Parry, D. Gray and A. Badhwar (2011).
"Compartment syndrome-induced microvascular dysfunction: an experimental rodent
model." Can J Surg 54(3): 194-200.
Ley, K., C. Laudanna, M. I. Cybulsky and S. Nourshargh (2007). "Getting to the site of
inflammation: the leukocyte adhesion cascade updated." Nat Rev Immunol 7(9): 678689.
Manjoo, A., D. Sanders, A. Lawendy, M. Gladwell, D. Gray, N. Parry and A. Badhwar
(2010). "Indomethacin reduces cell damage: shedding new light on compartment
syndrome." J Orthop Trauma 24(9): 526-529.
Motterlini, R., J. E. Clark, R. Foresti, P. Sarathchandra, B. E. Mann and C. J. Green
(2002). "Carbon monoxide-releasing molecules: characterization of biochemical and
vascular activities." Circ Res 90(2): E17-24.
Petrache, I., L. E. Otterbein, J. Alam, G. W. Wiegand and A. M. Choi (2000). "Heme
oxygenase-1 inhibits TNF-alpha-induced apoptosis in cultured fibroblasts." Am J Physiol
Lung Cell Mol Physiol 278(2): L312-319.
Petrova, N. L., P. K. Petrov, M. E. Edmonds and C. M. Shanahan (2015). "Inhibition of
TNF-alpha Reverses the Pathological Resorption Pit Profile of Osteoclasts from Patients
with Acute Charcot Osteoarthropathy." J Diabetes Res 2015: 917945.
Toyokuni, S. (1999). "Reactive oxygen species-induced molecular damage and its
application in pathology." Pathol Int 49(2): 91-102.
Urquhart, P., G. Rosignoli, D. Cooper, R. Motterlini and M. Perretti (2007). "Carbon
monoxide-releasing molecules modulate leukocyte-endothelial interactions under flow." J
Pharmacol Exp Ther 321(2): 656-662.
Whitesides, T. E., H. Hirada and K. Morimoto (1977). "Compartment syndromes and the
role of fasciotomy, its parameters and techniques." AAOS Instr Course Lect 26: 179.

130

APPENDICES

131
APPENDIX I.

I.1

PERMISSION TO USE COPYRIGHTED MATERIALS

Operative Techniques: Orthopaedic Trauma Surgery 2010;

Compartment Syndrome: Evidence-Based Approaches, Elsevier, pp.679-702

132

133
APPENDIX II: HUMAN RESEARCH ETHICS BOARD APPROVAL LETTER
Use of Human Participants – Ethics Approval Notice

Research

Principal Investigator: Dr. Abdel-Rahman Lawendy
Review Number: 17889E
Review Level: Delegated
Approved Local Adult Participants: 100
Approved Local Minor Participants: 0
Protocol Title: Identification of Serum Inflammatory Markers in Compartment Syndrome
Department & Institution: Surgery, London Health Sciences Centre
Sponsor:
Ethics Approval Date: April 29, 2011
Expiry Date: March 31, 2017
Documents Review & Approved &Documents Received for Information:

Document Name
UWO Protocol
Letter of Information & Consent

Comments Version Date
2011/01/20

This is to notify you that the University of Western Ontario Research Ethics Board for Health Sciences Research
Involving Human Subjects (HSREB) which is organized and operates according to the Tri-Council Policy Statement:
Ethical Conduct of Research Involving Humans and the Health Canada/ICH Good Clinical Practice Practices:
Consolidated Guidelines; and the applicable laws and regulations of Ontario has reviewed and granted approval to the
above referenced revision(s) or amendment(s) on the approval date noted above. The membership of this REB also
complies with the membership requirements for REB’s as defined in Division 5 of the Food and Drug Regulations.
The ethics approval for this study shall remain valid until the expiry date noted above assuming timely and acceptable
responses to the HSREB’s periodic request for surveillance and monitoring information. If you require an updated
approval notice prior to that time you must request it using the UWO Updated Approval Request Form.
Members of the HSREB who are named as investigators in research studies, or declare a conflict of interest, do not
participate in discussion related to, nor vote on, such studies when they are presented to the HSREB.
The Chair of the HSREB is Dr. Joseph Gilbert. The UWO HSREB is registered with the U.S. Department of Health &
Human Services under the IRB registration number IRB 00000940.
____________________________________

Signature

Ethics Officer to Contact for Further Information
_____ Janice Sutherland
(jsutherl@uwo.ca)

_____ Elizabeth Wambolt
(ewambolt@uwo.ca)

__✓___ Grace Kelly
(grace.kelly@uwo.ca)

134
VITA
Name:

Michel Andre Taylor

Post-secondary
Education and
Degrees:

University of Toronto
Toronto, Ontario, Canada
2002 – 2006 BSc
University of Western Ontario
London, Ontario, Canada
2007 – 2011 MD
Queen’s University
Kingston, Ontario, Canada
2011 – 2016 FRCSC (Orthopaedic Surgery)
University of Western Ontario
London, Ontario, Canada
2016 – 2017 Fellowship (Trauma)
Duke University
Durham, North Carolina, United States
2017 – present Fellowship (Foot and Ankle Surgery)

Honours and Awards:

Province of Ontario Graduate Scholarship
2016-2017
James and Connie Dickson Scholarship Sciences and Math.
2005, 2006

Related Work Experience: Research Assistant
University Health Network, Toronto, Ontario
2006 – 2007
Research Assistant
Hospital for Sick Children, Toronto, Ontario
2006 – 2007
Publications:
Taylor MA, Hopman W, Yach J (2016). Length of Stay, Wait Time to Surgery and 30day Mortality for Patients with Hip Fractures after the Opening of a Dedicated
Orthopaedic Weekend Trauma Room. Can J Surg. 59(5): 337-341.

135
Taylor MA, McKay D, Eid M, Schuklenk U, Pichora D (2015). What are the Ethical
Issues in Treating a Patient with Bilateral Leg Gangrene Incapable of Consenting to
Amputation Secondary to Psychiatric Illness? A Surgical, Psychological, and Ethical
Dilemma. Clin Orthop Relat Res. 473: 3998-4003.
Taylor MA, Pichora DR (2015). Forequarter amputation following pre-operative
embolization to treat two upper extremity malignancies in a previously irradiated
tissue bed: A case report. Orthop Muscul Syst. 4:187.
Taylor MA, Wood GCA (2014). Revision Total Hip and Total Knee Arthroplasty for
Massive Bone Loss and Periprosthetic Fracture Using a Total Femur Prosthesis: A Case
Report. Orthop Muscular Syst Curr Res. 3; 179.
Taylor MA, Yen D (2013). Single level anterior cervical discectomy and fusion with
polyetheretherketone (PeeK) prevail cages versus graft and plating technique. Can J
Surg. 56(4 Suppl. 2), S74.
Taylor MA, Wood GCA (2016). Pathophysiology of femoroacetabular impingement. In
Ayeni OR, Karlsson J, Philippon MJ, Safran MR. (1st Edition), Diagnosis and
Management of Femoroacetabular Impingement: An Evidence-Based Approach. Spring
International Publishing AG.

